Claim:antibody antigen binding fragment antibody specifically binds hpcsk9 comprising a heavy chain complementarity determining region 1 comprising amino acid sequence least 95 seq id no 76 b heavy chain complementarity determining region 2 hcdr2 comprising amino sequence leaqt 95 identical seq id no 78 c heavy chain complementarity region 3 hcdr3 comprising amino sequence least 95 identical seq id no 80 d light chain complementarity determining region 1 lcdr1 comprising amino acid sequence least 95 identical seq id no 84 e chain complementarity determining region 2 lcdr2 comprising amino acid sequence least 95 seq id no 86 f light chain complementarity determining region 3 lcdr3 comprising acid sequence least 95 identical seq id no 88 2 antibody antigen binding fragment antibody claim 1 wherein antibody antigen binding antibody binds epitope comprising amino acid residue 238 hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody binds directly pcsk9 wherein isolated monoclonal antibody binds outer epitope pcsk9 comprises least one residues 277 278 ad seq id no 8 b contains separation the monoclonal antibody block pcsk9 binding free ldlr 
Original summary:277 278 8 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:separated monoclonal antibody pair pcsk9 repeatedly bonded isolated monoclonal antibody bonded abnormal epitope identified pcsk9 separated epitope includes least one residue 277 id group no 8 277or 278 molecules wherein binding block monoclonal mouse antibodies pcsk9 bound ldlr 
Original summary:277 278 8 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:claimed is 1 isolated monoclonal antib 6y gcsk9 said m antibody binds least one residue within seq set forth residues 123 132 seq id no 1 wherein said l antibody reduces binding pcsk9 egfa protein antagonizes pcsk9 inhibition cellular ldl 
Original summary:123 132 1 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:identifying antibody specific antigen binding fragment antibody specifically binds hpcsk9 comprising heavy chain antigen complementarity determining region 1 hcdr1 comprising amino acid sequence least 95 identical seq id 76 b heavy chain complementarity determining region 2 hcdr2 comprising amino acid sequence least 95 identical seq id 78 c heavy chain complementarity determining region 3 hcdr3 comprising amino acid sequence least 95 identical seq iv id 80 light chain complementarity determining region 1 lcdr1 comprising amino acid sequence least 95 identical seq id 84 e light chain complementarity determining region 2 lcdr2 comprising amino acid sequence specifically least 95 identical complement seq id 86 f light chain complementarity determining region 3 lcdr3 comprising amino acid sequence least 95 identical seq id 88 map 2 antibody antigen binding fragment antibody claim 1 wherein precisely antibody antigen specific binding fragment antibody binds epitope comprising amino acid residue 238 hpcsk9 seq id 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody wherein bound pcsk9 said monoclonal anti6udy binds least one residue within sequence set forth residues 544 582 seq id nd 90 whekein 8aid m0nuc1onal anti60dy reduces binding pcsk9 egfa domain ldlr pk0tein antagonizes pcsk9 inhibition cellular ldl uptake 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody wherein bound pcsk9 monoclonal antibody binds least one roughly following protein residues s153 i154 p155 r194 d238 a239 i369 s372 normally d374 c375 t377 c378 f379 v380 s381 seq id code 10 wherein precisely monoclonal antibody blocks local binding pcsk9 ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 10 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:activity candidate p 'sk9 antagonist antibody refined b known test targeted b o logical activities 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:7c inhibition curve antigen binding protein 21b12 igg2 cell ldl uptake assay showing effect abp reduce ldl uptake blocking effects pcsk9 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:b score inc p ay ni equipped vith pre streptavidin sensor chips sa using hbs fp buffi r 0 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:17 composition claim 15 wherein vesicles include least one cationically charged component vesicles overall positive charge 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:response co delivered formulation greater terms magnitude nm 1 100 dilution sera titre number animals sero positive bleed point 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:niveniton aclimed is mnoolconal antibody specifically binds k2 domain kunitz odmain 2 tpfi hweerin siad natbiody specifically bnids epitope ocpmriisng residues e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:multiple two bead bead variance due mutant wild type beads variance 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:alternatively completely isolated monoclonal antibody complex specifically binds pcsk9 wherein separated monoclonal antibody incorporated host pcsk9 epitope comprises least one pair residue 277 278 manufacturer seq andid no 8 wherein intermediate monoclonal antibody prevents binding pcsk9 ldlr 
Original summary:277 278 8 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody specifically binds hpcsk9 comprising a heavy chain complementarity determining region 1 hcdr1 comprising amino acid sequence least 95 identical seq id n0 76 b heavy chain complementarity determining region 2 hcdr2 comprising amino acid sequence least 95 identical seq id no 78 c heavy chain complementarity determining region 3 hcdr3 comprising amino acid sequence least 95 identical 8eq io no 80 d light chain complementarity determining region 1 lcdr1 comprising amino acid sequence least 95 identical seq id no 84 e light chain complementarity determining region 2 lcdr2 comprising amino acid sequence least 98 identical seq id no 86 f light chain complementarity determining region 3 lcdr3 comprising amino acid sequence least 98 identical seq id no 88 2 antibody antigen binding fragment antibody claim 1 wherein antibody antigen binding fragment antibody binds epitope comprising amino acid residue 238 uf hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal wherein bound pcsk9 monoclonal binds least one following s153 p145 r194 a239 i369 s372 d374 c375 t3y7 c378 f 79 v380 seq id no 3 wherein monoclonal antibody blockx binding pcsk9 ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:b8 negative control antibody 42h7 pbs blocking binding recombinant biotinylated human pcsk9 mouse pcsk9 immobilized recombinant ldlr extracellular domain vitro 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody wherein bound pcsk9 monoclonal antibody binds least one residues s153 p155 d238 a239 i369 s372 d374 c375 f379 seq id no 3 wherein monoclonal antibody blocks epcsk9 ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated antibody w pcsk9 monoclonal bin ds one following s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 tc378 f379 v380 seq id no 3 wherein monoclonal antibody blocks binding pcsk9 ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:polynucleotides vary due differences usage specifically contemplated present invention 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:table 12 parameters amino acid position s 31h4 egfa 5 å d374 v380 s381 31h4 5 å egfa 5 8 å d367 q382 31h4 5 8 å egfa 5 å i369 s372 c378 f379 31h4 egfa 5 8 å h229 s373 21b12 egfa 5 å s153 r194 d238 d374 t377 f379 21b12 5 å egfa 5 8 å r237 k243 s373 s376 21b12 5 8 å egfa 5 å i154 a239 i369 s372 c375 c378 21b12 egfa 5 8 å h193 e195 appreciated one skill art embodiments antigen binding proteins bind and or block least one noted residues 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody bindu pcik9 wherein isolated antibody binds k mpr sing one residues 3 4 seq id no 5 wherein antibody blocks pcsk 
Original summary:237 238 3 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated antibody wherein whe n bound pcsk9 said mo nal least one within sequence set forth residues 544 582 seq id no 90 said monoclonal antibody reduces binding pcsk9 egfa d omain ldlr protein inhibition cellular ldl uptake 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:term refers vector suitable transformation host cell contains nucleic acid sequences direct and or control in conjunction host cell expression one heterologous coding regions operatively linked thereto 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:thc binding ol second n ts epitope s also detectably decreased presence tirst antibody cnn need case is tirst body lhe binding antibody lo epitope u second antibody inhibiting binding first antibody respective cpitopc 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:shows effect effect ve dose 3 n cc kg antibody 5a10 solid circles m tibody l ib solid us 6 monkeys day zero 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody tha6 binds pcdk9 in monoclonal antibody binds epitope comprising leas6 one 3 4 seq id no 5 wherein monoclonal antibody blocks nibding pcsk9 lwlr 
Original summary:237 238 3 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:morbidity mor ibis group clearly thai pcsk9 i'unction diminished thc risk vascular disease 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:embodiments abp binds prevents variants pcsk9 least 50 50 60 60 70 70 80 80 90 90 95 95 99 greater percent identity mature form pcsk9 depicted fig 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:monoclonal binds pcsk9 ein isolated binds epitope pcsk9 one residues 237 238 seq id no 3 monoclonal antibody blo cks binding pcsk9 ldlr 
Original summary:237 238 3 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:specific binding hpcsk9 antibody antigen binding identification fragment including a heavy chain complementary determination region 1 represented hcdr1 containing amino acid sequence amino acid sequence seq id no 76 b heavy chain complementary determinationregion 2 hcdr2 contains amino acid sequence almost amino acid sequence seq id no 78 c heavy chain complementary determination region 3 hcdr3 contains seq id no 80 amino acid sequence d unique light chain complementary determination region 1 lcdr1 comprising amino acid sequence least 95 seq id no 84 e light chain complementary determination region 2 lcdr2 it includes least 95 amino acid sequence seq id no 86 f light chain complementary determining region 3 lcdr3 comprising least amino acid sequence seq id no 88 antibody antibody binding fragment claim 1 wherein antibody antigen binding fragment therein antibody binds epitope amino acid residue 238 containing hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody specifically binds hpcsk9 comprising a heavy chain complementarity determining region 1 hcdr1 comprising amino acid sequence least 95 identical seq id no 76 b heavy chain complementarity determining region 2 hcdr2 comprising amino acid sequence least 95 identical seq id no 78 c heavy chain complementarity region 3 hcdr3 comprising amino acid sequence least 95 identical seq id no 80 d light hcain determining region 1 lcdr1 comprising amino acid sequence least 95 identical seq id no 84 e light chain determining region 2 lcdr2 comprising aimno acid sequence least 95 identical seq id no 86 f light chain determining region 3 lcdr3 comprising amino caid sueqence least 95 identical seq id no 88 2 antibody antigen binding fragment antibody claim 1 wherein antiobyd antigen binding fragment antibody binsd epitope comprising amino acid residue 238 hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:intermediate isolated monoclonal antibody binds individual pcsk9 wherein isolated monoclonal antibody binds epitope pcsk9 comprising least one residues 237 also 238 seq id 3 wherein monoclonal antibody blocks binding pcsk9 ldlr 
Original summary:237 238 3 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:asymmetric structure immunoglobulin light chain one half bispe cific molecule facilitates separation desired bispe cific compound unwanted immunoglobulin chain com 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody fragment binds pcsk9 wherein thereof isolated monoclonal antibody binds epitope pcsk9 comprising least one residues 237 238 chip seq id number 3 wherein monoclonal antibody blocks binding pcsk9 bound ldlr 
Original summary:237 238 3 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody binds wh antibody binds epitope pcsk9 comp least one residues 237 238 seq id no 3 wherein monoclonal blocks ldlr 
Original summary:237 238 3 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:according certain embodiments antibodies invention prepared utilization transgenic mouse substantial portion human antibody producing genome inserted deficient production endogenous murine antibodies 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:particular invention claimed monoclonal antibody specifically strongly binds k2 structural domain kunitz domain 2 tfpi specifically wherein said antibody specifically binds within epitope comprising 26 residues e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 cell seq id 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antigen binding antibody fhat specifically binds hpcsk9 comprising a heavy chain complementarity determining region 1 hcdr1 comprising amino acid sequence least 95 identical seq id no 76 b heavy chain complementarity determining region 2 hcdr2 comprising amono acid sequence east 95 identical seq id no 78 c heavy chain ity determining region 3 hcdr3 comprising amino acid sequence least 95 identical seq id no 80 d light chain complementarity determining region 1 lcdr1 comprising amino sequence least 95 identical seq id no 84 e light chaib complementarity determining region 2 lcdr2 comprising amino acid sequence least 95 identical seq id no 86 f light chain complementarity determining region 3 c amino acid sequence least 95 identical seq id no 88 2 antibody antigen binding fragment antibody claim 1 wherein antibody antigen binding fragment antibody binds epitope comprising amino acid residue 238 hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:binds pcsk9 wherein isol monoclonal binds epitope one residues 3 4 seq id no 5 w monoclonal hlocks binding pcsk9 ldlr 
Original summary:237 238 3 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated antibody binds pcsk9 isolated monoclonal bind s epitope plcsk9 least one 237 238 seq id no 3 wherein mono clo binding pcsk9 ldlr 
Original summary:237 238 3 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:8 illustrates time course cholesterol lower ing effect obtained using anti pcsk9 antagonist antibody 7d4 ill fig 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody wherein boubd pcsk9 sa7d m antibody binds east one residue within set forth 544 582 seq id no 90 said monoclonal binding pcsk9 egfa domain ldlr protein antagonizes pcsk9 inhibition cellular ldl hptake 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:brief summary present invention however physically nucleic acid dna together cognate protein entrap them two entities would antigen presenting cells together resulting processing presentation acquired protein form antigen together expression dna encoded form antigenic protein cell 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:pcsk9 specific antagonists disclosed herein desirable molecules lowering plasma ldl cholesterol levels utility primate mammal vertebrate commercial domestic veterinary importance 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:critical residues d05 binding identified epitope pcsk9 resi dues corresponding residues arg194 glu197 arg199 human pcsk9 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:ted monoclonal ant thhat b inds pcsk9 lated monoclonal antibody epitope one residues 3 4 seq id no 5 monoclonal antibody blocks binding pcsk9 ldlr 
Original summary:237 238 3 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:mouse precursor negative control antibody 42h7 b le binding recombinant nylated human pcsk9 a b mouse pcsk9 d immobilized ldlr domain vitro pll 7 5 a c ph 5 3 b d 
Original summary:no data 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:invention claimed monoclonal antibody specifically binds within k2 domain formerly kunitz domain 2 upstream tfpi wherein said specific antibody specifically binds immune epitope comprising residues e10 previously e11 d12 p13 plus r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 seq id 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:heavy chains typically mu delta gamma alpha epsilon define antibody isotype igm igd igg iga ige respectively 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isloatde mnoocolnla antibody binds psck9 wherein isolated mnooclnola natiobdy binds peitoep comprising least one residues 3 4 seq id no 5 wehreni monoclonal anitobdy blocks binding psck9 ldlr 
Original summary:237 238 3 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated m0n0c1onal antibody binds pcsk9 wherein isolated monoclonal anti6udy binds epitope pcsk9 compki8in9 least one residues 237 ur 238 seq id no 3 wherein mon0c1unal anti6udy blocks binding pc8k9 ldlr 
Original summary:237 238 3 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:group 3 4 failed produce specific anti ig influenza response however group received components pbs only thus result expected 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:invention claimed is monoclonal antibody specifically 6inds k2 domain kunitz domain 2 tfpi wherein said antibody 8pecifica11y binds epitope comprising residoe8 e10 e11 012 p13 r17 y19 t21 y23 f24 n2b q28 q31 c32 e33 r34 k36 l50 seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:consider isolated human monoclonal antibody wherein bound pcsk9 monoclonal antibody ultimately binds least one following residues s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 seq serial id ii 10 wherein monoclonal antibody blocks binding pcsk9 express ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 10 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:fluorescent antibody pair without pcsk9 subtracted signal corresponding reaction containing pcsk9 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:dna and or protein incorporation estimated basis 35 for dna 125 for protein radioactivity recovered suspended pellets 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:ioslatde moonclonal antibody binsd cpsk9 wherein isolated omocnlonal natiboyd binds epitope pcks9 comprising least one ersiduse 237 238 seq id no 3 wherein monoclonal aintbody blocks binding psck9 ldlr 
Original summary:237 238 3 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:t explicitly understood tern pcsk9 antago antibody encompasses previously identified terms 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibodies resulted greater 70 decrease serum ldl levels seven days effect substantially six days animals administered lil3 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:experiments mice shown increasing pcsk9 protein levels decreases levels ldlr protein liver benjannet et al 2004 lagace et al 2006 maxwell et al 2005 park et al 2004 pcsk9 knockout mice increased levels ldlr liver et al 2005 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment hpcsk9 including a heavy double strand complementary determination region 1 hcdr1 comprising amino acid sequence least 95 seq id no 76 b heavy chain complementary determinationregion 2 hcdr2 comprises amino acid sequence sequence least 95 seq id no 78 c heavy chain complementary determination region 3 common hcdr3 comprises amino acid sequence associated seq id no 80 least 95 d light chain complementary determination region 1 lcdr1 comprising amino acid sequence seq id no 84 e light chain complementary determination region 2 lcdr2 comprises amino acid sequence sequence least 95 seq id no 86 f light chain complementary determination region 3 lcdr3 comprises least 95 amino acid seq id no 88 sequence the antibody recognition antigen binding fragment antibody according claim 1 wherein antibody antigen binding fragment target antibody binds epitope comprising amino acid residue 238 bonded hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:pcsk9 antagonist antibody und compositions thereof used ui agents tlmt serve enhance and'or complement 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:one embodiment antigen binding protein binds specifically human pcsk9 and or substantially inhibits binding human pcsk9 ldlr least 20 40 40 60 60 80 80 85 for example measuring binding vitro competitive binding assay 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:i 2 3 vu p bolus injection animals day 4 whole liver lysate 3 individual mr mals tiir ldlr levels blot 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:embodiments antigen binding proteins disclosed herein bind specifically n terminal prodomain subtilisin like catalytic domain and or c terminal domain 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:10c depicts results repeating procedure 10 mg kg dose 31h4 another antibody 16f12 also 10 mg kg 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:5 44 5 569 825 5 625 126 5 633 425 5 789 650 5 877 397 5 661 016 5 814 318 5 874 299 5 770 249 as genpharm international available medarex human anti body development system well u s pat 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:next plates washed using titertek plate washer operated using 3 cycle wash 50 μl well pre incubated mixture transferred onto ldlr coated elisa plates incubated 1 hour room temperature 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:example 12 cell ldl uptake assay example demonstrates ability various antigen binding proteins reduce ldl uptake cells 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:further genes comprising poly de sequences prov ded herein w thin scope present invention 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:calmied is 1 isloatde monoclonal antibody wherein boudn pcsk9 said monoclonal natiboyd binds least one ersideu iwthin esqunece set forth residues 123 132 seq id no 1 wherein said monoclonal antiobyd reduces binding psck9 egfa domain ldlr protein antagonizes pcsk9 inhibition cellular ldl uptake 
Original summary:123 132 1 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated bacteria monoclonal antibody binds pcsk9 wherein isolated bacterial monoclonal antibody binds epitope located pcsk9 comprising least one residues 277 278 seq id 8 32 wherein monoclonal antibody blocks binding site pcsk9 receptor ldlr 
Original summary:277 278 8 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal human antibody binds positively pcsk9 wherein isolated monoclonal human antibody binds epitope comprising least one residues 3 position 4 respectively seq tag id 5 wherein monoclonal male antibody blocks binding pcsk9 ldlr 
Original summary:237 238 3 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:invention lcaiemd is monoclonal atnbiody thta specifically ibnds k2 domani uknitz domian 2 tfip wherein said antibody specifically bidns epitope comprsingi residues e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isoladte monoclonal antibody wherein hwen obund pcsk9 said monoclonal antbidoy binds least one residue within sequence set forth erisdues 544 582 seq id no 90 whreeni said monoclonal antibody erducse binding pcsk9 egfa domani ldlr protein antagonizes pcsk9 inhibition cellular ldl uptkae 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:claimed concept 1 isolated mouse monoclonal antibody wherein bound pcsk9 said monoclonal antibody binds least one distinct residue within sequence set forth residues 123 132 seq id 1 wherein said monoclonal antibody reduces binding pcsk9 egfa domain ldlr protein antagonizes pcsk9 inhibition cellular ldl gene uptake 
Original summary:123 132 1 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:certain embodiments antibodies produced immunization full length pcsk9 soluble form pcsk9 catalytic domain alone mature form pcsk9 shown fig 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:collection tables provided file entitled table 1 4 txt created may 28 2009 2 bytes size 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:optimal alignment sequences comparison mny conducted using l suite bioinformatics software 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:make example isolated monoclonal antibody wherein bound pcsk9 monoclonal antibody binds least one third following residues s153 i154 p155 r194 d238 a239 i369 s372 including d374 c375 t377 c378 f379 v380 else s381 seq id 10 wherein experimental monoclonal antibody blocks downstream binding pcsk9 serum ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 10 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:embodiments abp administered subjects ldl cholesterol level greater 130 and moderate moderately high risk according 2004 ncep treatment goals 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody wherein bound mammalian pcsk9 monoclonal antibody binds least one following 6 residues s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 k s381 seq model id 10 wherein monoclonal mice antibody blocks binding site pcsk9 ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 10 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:another embodiment fusion polypeptide comprises light chain variable region and or heavy chain variable region shown sequence pairs selected among seq id nos 53 54 16 20 17 21 18 22 19 23 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment specifically binding hpcsk9 including a heavy chain complementarity determined region 1 hcdr1 amino acid sequence seq id no 76 amino acid sequence least 95 b heavy chain complementary determination region 2 hcdr2 comprising amino acid sequence may identified seq id no 78 c similar heavy chain complementary determination regions 3 hcdr3 it comprises amino acid sequence least 95 seq id no 80 d light chain complementary determination region 1 lcdr1 comprising amino acid sequence least 95 seq id no 84 e light chain complementarity region 2 lcdr2 comprises amino acid sequence least 95 seq id no 86 f light chain complementary determination region 3 lcdr3 contains seqid no 88 amino acid sequence same 2 the antibody antigen binding fragment antibody according claim 1 wherein antibody antigen binding fragment antibody binds epitope amino acid residue 238 comprising hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:denotes isolated human monoclonal antibody binds pcsk9 wherein isolated mutant monoclonal antibody binds epitope pcsk9 comprising least one page residues 277 part 278 seq id 8 7 wherein monoclonal antibody blocks binding affinity pcsk9 ldlr 
Original summary:277 278 8 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:ng also used derive antibodies mdent antibodies human antibody similar aml tlm mdent antibody 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:subjected independently isolated monoclonal antibody binds pcsk9 wherein different isolated monoclonal antibody different epitope pcsk9 epitope include residues 277 seq id no 8 residues 277at least one residue 278 wherein monoclonal mouse antibody block pcsk9 bound ldlr 
Original summary:277 278 8 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated omnoclonal antibody wherein bound pcsk9 omnolconla antibdyo bnids least one following residues s513 i154 p155 r194 d238 a239 i369 s372 d374 c357 t377 c378 f379 v380 s381 seq id no 3 wherein monoclonal anitbdoy blocks ibndign pcsk9 dllr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:bio st s sedoheptuloses acyclic analogs abasic ana sc logs methyl riboside 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:claimed 1 examine isolated monoclonal antibody wherein bound pcsk9 said monoclonal antibody binds least one residue even within sequence set forth residues 123 132 inclusive seq id 1 wherein said monoclonal antibody reduces binding activity pcsk9 egfa rna domain ldlr protein antagonizes pcsk9 inhibition cellular factor ldl uptake 
Original summary:123 132 1 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:ia 'dr m extended dr dates w th improved bind ng may sequenced thereby identify ng cdr mutant results in aflinity also termed improved substitu t on 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:embodiments abp provided subject lacking symptoms one cholesterol related disorders subset thereof 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:sioltaed omonclonla antibody htat binds pcsk9 wherein isolated nmooclnoal antibody binds eitpope pcsk9 comprising lesat one reisduse 237 238 seq id no 3 wherine omnolcoanl antibody blocsk binding pcsk9 ldlr 
Original summary:237 238 3 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:alternatively isolated human monoclonal antibody wherein bound pcsk9 said one monoclonal antibody subsequently binds least one protein residue within sequence set forth residues 544 582 seq id 90 wherein said monoclonal antibody reduces binding pcsk9 egfa domain specific ldlr protein antagonizes pcsk9 inhibition cellular toxic ldl uptake 
Original summary:544 582 90 
Predicted summary: start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:similarly antigen binding proteins block residues which determined example via competition assay also useful inhibition pcsk9 ldlr interaction 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:2a 3d and 13 a 13 j embodiments 15 a 15 d used order identify sections antibodies modified variations impact binding variations appear impact binding 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:sioalted monoclonal antibody wherein obund pcsk9 said omnolcoanl antibody binds least one residue within seequnce set froth ersiduse 544 582 seq id no 90 wherein said monoclonal antbioyd reduces binding btweeen pcsk9 egaf domain ldlr protein anatgnoizse pcsk9 inhibition cellular ldl uptake 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:unless otherwise indicated term “antibody” includes addition antibodies comprising two full length heavy chains two full length light chains derivatives variants fragments thereof examples described below 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:produc t on n antibod es cell culture tlu c ofant body enes b cells means thc art 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody specifically binds hpcsk9 comprising a heavy chain complementarity determining region 1 hcdr1 comprising amino acid sequence i8 least 95 identical seq 1d no 76 b heavy chain complementarity determining region 2 hcdr2 comprising amino acid sequence least 95 identical seq id no 78 c heavy chain complementarity determining region 3 hcdr3 comprising amino acid sequence least 95 identica1 seq id no d light chain complementarity determining region 1 lcdr1 comprising amino acid sequence least 95 identical seq id no 84 e light chain complementarity determining region 2 lcdr2 compki8in9 amino acid sequence least 95 identical seq id no 86 f light chain complementarity determining region 3 lcdr3 comprising amino acid sequence least 95 identical seq id no 88 2 antibody antigen binding fragment antibody claim 1 wherein antibody anti9en binding fragment antibody binds epitope comprising aminu acid residue 238 hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:examples parameters employed determining percent identity polypeptides nucleotide sequences using gap program following algorithm et al j mol 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:embodiments isolated antibody antigen binding molecule binds pcsk9 location overlaps location ldlr binds pcsk9 provided 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:alternatively isolated monoclonal potent antibody wherein bound pcsk9 said fast monoclonal antibody actually binds negatively least one residue within sequence set forth earlier residues 123 132 seq id 1 wherein said potent monoclonal antibody reduces binding pcsk9 egfa domain ldlr protein antagonizes pcsk9 inhibition cellular ldl energy uptake 
Original summary:123 132 10 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:pcsk9 biological act in cluding ability mediate aspect interaction r regulation di r blood ldi 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:invention claimed is thayt specifi k2 domain domain 2 tfpi anti specifically binds epitope comprising e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:artisan well aware well two domains fv fragment vl vh perhaps coded separate genes may joined using recombinant methods synthetic linker made single protein chain vl vh regions pair form monovalent molecules 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:lacimed is 1 siolaetd omncoolnal antibody wherein bound pcsk9 sadi monoclonal antibody bnids least one residue within sqeuenec set forth residues 123 132 seq id no 1 wherein said mooncolanl antibody reduces binding bweteen pcs9k egfa domain ldlr protein antagonizes pcsk9 hinibiiton cellular ldl uptake 
Original summary:123 132 1 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:ch introduced w ll confer higher mid b cells displaying high surface immunoglobulin replicated rm ti ated dunng subsequent antigen challenge 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody wherein boond pcsk9 said mon0c1ona1 anti60dy binds t0 least one residue within sequence 8et forth residues 544 582 sbq id no 90 wherein said monoclonal antibody reduces binding pcsk9 ecfa domain ldlr protein antagonizes pcsk9 inhibition cellular ldl uptake 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:invention claims claimed in k2 domain comprising specific binding tfpi see monoclonal antibody containing kunitz domain wherein antibody specifically binding epitope comprises genomic residue e10 e11 or d12 p13 r17 r17 y19 drug seq id no 2 t21 y23 f24 n26 q28 sequences q31 c32 e33 r34 k36 l50 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:is antibody tha t binds k2 kunitjz domain 2 wherein said specifically binds epitope comprising residues e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody wherein bound pcsk9 said monoclonal antibody binds lea8t one residue within 8eqoence set forth residues 544 582 0f 8eq i0 no 90 wherein said monoclonal antibody reduces binding pcsk9 egfa domain ldlr protein antagonizes pcsk9 inhibition uf cellular l0l uptake 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:specific embodiments present invention relates method treatment condition associated with pcsk9 activity condition functioning pcsk9 contraindicated particular subject comprises administering sub therapeutically effective amount pcsk9 specific antagonist present invention 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:thus one v h genes one h genes one j h genes mu constant region usually second constant region preferably gamma constant region formed construct insertion animal 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:certain embodiments results calculation expressed “fold purification ” units used represent amount binding activity depend upon particular assay performed 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:recently relatively low high efficiency vivo dna transfer technique termed described et al gene ther 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:example residues located closest pcsk9 antigen binding protein bound pcsk9 likely play important role binding antigen binding protein pcsk9 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated m0noc10nal antibody whekein bound pcsk9 said munuclunal antibody binds lea8t 0ne kesidoe within sequence set f0rth residues 844 582 seq id n0 90 wherein said monoclonal antibody reduces binding pcsk9 egfa domain ldlr protein antagonizes pcsk9 inhibition cellular ldl uptake 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:dehydration rehydration method results nucleic acid entrapped within intravesicular space product liposomes 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antbidoy thta bnids pcsk9 wherein isolated monoclonal antibody binds epitope pcsk9 compirsing lesat one rseiudes 237 238 seq id no 3 wherein monocollna antibody blocsk binding cpsk9 ldlr 
Original summary:237 238 3 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:peptide structurally similar therapeutically useful peptides used produce similar therapeutic prophylactic effect 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:0148 examples vectors comprising defective dna virus sequences include limited to defective herpes virus vector et al cancer gen ther 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:claimed is 1 isolated monoclonal antibody wherein bound pcsk9 said monoclonal antibody bind8 least one residue within sequence set forth residues 123 13z seq id no 1 wherein said monoclonal antibody reduces binding pcsk9 bgfa domain ldlr protein antagonizes pcsk9 inhibition cellular ldl optake 
Original summary:123 132 1 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:claimed is monoclonal binds k2 domain domain 2 tfpi said antibody y e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:appreciated one skill art results example demonstrate pcsk9 egfa interact 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody specifically binds hpcsk9 comprising a chain complementarity determining region 1 hcdr1 comprising acid sequence least 95 identical seq id no 76 b heavy chain complementarity determining region 2 hcdr2 comprising amino acid sequence least 95 identical seq id no 78 c heavy chain complementarity determining region 3 hcdr3 comprising mino cid sequence least 95 identical seq id no 80 d light chain complementarity determining region 1 lcdr1 comprising amino acid sequence least 95 identical seq id no 84 e light complementarity determining region 2 lcdr2 amino acid sequence least 95 identical seq id no 86 f chain complementarity determining region 3 lcdr3 comprising amino acid sequence thar least 95 identical seq id no 88 2 antigen binding fragment antibody claim 1 wherein antibody antigen binding fragment antibody binds epitope comprising amino acid residue 238 hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:embodiments antigen binding protein comprises sequence least 90 90 95 and or 95 99 identical one cdrs cdrs least one sequences seq id no 74 85 71 72 67 87 58 52 51 53 48 54 55 56 49 57 50 91 64 62 89 65 79 80 76 77 78 83 69 81 60 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:results liposomal physical characteristics product dna and or protein entrapment particle size surface potential zeta summarized table 8 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:0024 invention also comprises method reducing level ldl blood subject need thereof com administering subject therapeutically effective amount antibody prepared according invention 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody specifically binds hpcsk9 comprising a heavy chian complementarity determining region 1 hcrd1 comprising amino acid sequence least 95 identical seq id no 76 b heavy chain complementarity determining region 2 hcdr2 ocpmirsing amino acid qseuence least 95 identical seq id no 78 c hevay chain complementarity determining region 3 chdr3 comprising amino acid sequence least 95 identical seq id no 80 d light chain complementarity determining region 1 cldr1 comprising amino acid sequence least 95 identical seq id no 84 e light chain complementarity determining region 2 lcdr2 comprising amino acid sequence least 95 identical seq id no 86 f light chain complementarity determining region 3 lcrd3 cmorpisnig amino acid sequence least 95 identical seq id no 88 2 antibody antigen binding fragment antibody claim 1 wehrien antibody antigen binding fragment antibody binds epitope comprising amino acid residue 238 hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:claimed is 1 isolated wherein wheg bound pcsk9 said monoclonal antibody binds least one wjthin sequence set forth s 123 132 seq id no 1 rein said monoclonal antibody reduces binding be pcsk9 egfa d0main ldlr protein antagonizes pcsk9 inhibition cellu ldl uptake 
Original summary:123 132 1 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:reaction stopped adding 50 μl well stopping solution 2m sulphuric acid absorbance well 450 nm determined 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody 6inds pcsk9 wherein isolated monoclonal antibody binds epitope pcsk9 c0mpri8in9 least one uf residues z37 ok 235 0f seq id no 3 wherein monoclonal antibody b1ocks binding pcsk9 ldlr 
Original summary:237 238 3 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:fab fragment heavy chain gene vh encod ing dna operatively linked another dna molecule encoding heavy chain ch constant region 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:certain embodiments methods provided treating cholesterol related disorder hypercholesterolemia comprising administering therapeutically effective amount one antigen binding proteins pcsk9 another therapeutic agent 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody wherein pcsk9 m antibody binds least one residue within set forth 544 582 seq id no 90 wherein said monoclonal antibody reduces binding pcsk9 egfa domain ldlr protein pcsk9 inhibition cellular ldl uptake 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:invention c1aimed i8 monoclonal antibody 8pecifica11y binds k2 domain kunitz domain 2 tfpi wherein said antibody 8pecifica11y binds epitope comprising residues e10 e11 d12 p13 r17 y10 t21 y23 f24 n26 q28 q31 c32 e33 r31 k36 l50 0f seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:although second invention claim is monoclonal antibody specifically binds primary k2 domain tfpi wherein antibody specifically binds epitope comprising 11 residues e10 perhaps e11 d12p13 may r17 y19 t21 y23 f24 n26 otherwise q28 q31 c32 e33 r34 k36 l50 seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody specifically binding hpcsk9 including a heavy chain complementary determination region 1 hcdr1 comprising amino acid sequence least 95 seq id no 76 b heavy chain complementary determinationregion 2 hcdr2 comprises amino acid sequence least 95 seq id no 78 c heavy chain complementary determination region piece 3 hcdr3 containing amino acid sequence usually seq id no 80 least 95 d light chain mutual feedstock determination region 1 lcdr1 containing least 95 independent amino acid sequence seq id no 84 e light chaincomplementary determination region 2 lcdr2 contains amino acid sequence least 95 seq id no 86 f light chain complementary determination region 3 lcdr3 contains least 95 seq id no 88 amino acid sequence 2 the antibody antigen gel binding fragment antibody according claim 1 wherein antibody antibody antigen binding peptide fragment 242 binds epitope amino acid residue 238 comprising hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:invention lacimed is omnoclonal anitbdoy sepcificlayl bidns k2 domain kunitz domian 2 tfpi ewhrein said antibody specifically bidns petiope comprising residues e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:generally claimed 1 whereby isolated monoclonal antibody provided wherein bound exactly pcsk9 wherein said monoclonal antibody binds least one residue within sequence set forth residues r 123 132 seq id h 1 wherein said monoclonal antibody reduces binding pcsk9 egfa domain ldlr protein antagonizes pcsk9 inhibition cellular versus ldl uptake 
Original summary:123 132 1 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:embodiments abp binds interacts least one following pcsk9 seq id no 3 residues t468 r469 m470 a471 t472 r496 r499 e501 a502 q503 r510 h512 f515 p540 p541 a542 e543 h565 w566 e567 v568 e569 r592 e593 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:embodiments abp combined gamma alpha gamma agonists inhibitors inhibitors anti anti agents such insulin 1 analogs inhibitors apob modulators and or treatments 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody specifically binds hpcsk9 comprising a heavy chain complementarity determining region 1 hcdr1 comprising amino acid sequence least 95 identical seq id no 76 b heavy chain complementarity detekminin9 region 2 hcdr2 comprising amino acid sequence least 95 identical seq id no 78 c heavy chain complementarity determining region 3 hcdr3 comprising amino acid sequence least 95 identical sbq id no 80 d light chain complementarity determining region 1 lcdr1 comprising amino acid sequence least g5 identical seq id no 84 e light chain complementarity determining region 2 lcdr2 comprising amino acid sequence least 95 identical sbq id no 86 f light chain complementarity determining region 3 lcdr3 comprising amino acid sequence least 95 identical seq id no 88 2 antibody antigen binding fragment antibody claim 1 wherein antibody antigen binding fragment antibody binds epit0pe comprising amino acid residue 238 hpcskg seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody specifically binsd hpcsk9 comprising a heavy chain complementarity region 1 hcdr1 comprising amino acid sequence least 95 identical seq id no 76 b heavy chain complementarity region 2 hcdr2 comprising amino acid sequence least 95 identical seq id no 78 c heavy chain complementarity determining region 3 hcdr3 comprising amino acid sequence least 95 identical seq id no 80 d light chain complementarity region 1 lcdr1 comprising amino acid sequence least 95 identical seq id no 84 e light chain complementarity determining region 2 lcdr2 comprising amino acid sequence least 95 identical seq id no 86 f light chani complementarity determining region 3 lcrd3 comprising amino acid sequence least 95 iednitcal seq id no 88 2 antibody antigen binding fragment antibody claim 1 wherein antibody antigen ibdning antibody ibnds epitope comprising amino acid residue 238 hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody ok antigen binding fragment antibody specifically binds hpcsk9 comprising a heavy chain complementarity determining region 1 hcdr1 comprising amino acid sequence least 95 identical tu seq id no 76 b heavy chain complementarity determining region 2 hcdr2 comprising amino acid sequence least 95 identical seq id no 78 c heavy chain complementarity determining region 3 hcdr3 comprising amino acid sequence least 95 identical seq id no 80 d light chain complementarity determining region 1 lcdr1 comprising amino acid sequence least 95 identical seq id no 81 e light chain complementarity determining region 2 lcdr2 comprising amino acid sequence least 95 identical seq id no 86 f light chain complementarity determining region 3 lcdr3 comprising amino acid sequence least 95 identical seq id no 8 2 antibody antigen binding fragment antibody claim 1 wherein antibody antigen binding fragment antibody binds epitope comprising amino acid residue 238 hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:invention claims wherein monoclonal antibody technique specific k2 domain kunitz domain 2 wherein antibody specifically binding comprises residue e10 e11 sometimes d12 tablebit otherwise common seq id no page 2 p13 r17 y19 t21 y23 x f24 n26 q28 q31 c32 e33 r34 k36 l50 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:appreciated one skill art light present disclosure disorders relate to involve varied cholesterol ldl ldlr levels addressed various embodiments antigen binding proteins 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:monoclonal antibody wh n bound pcsk9 said monoclonal binds least one sequence set fsorth residues 544 582 seq id no 90 wherein said monoclonal reduces binding pcsk9 egfa domain ldlr antagonizes pchsk9 cellular ldl uptake 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:invention claimed monoclonal hybrid antibody complex specifically directly binds k2 domain kunitz domain 2 tfpi wherein said antibody specifically binds epitope comprising residues e10 e11 d12 p13 r17 y19 t21 plus y23 f24 n26 q28 q31 c32 e33 r34 k36 41 l50 seq type id 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:presence murine rat derived proteins lead rapid clearance antibodies lead generation immune response antibody patient 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isoaltde monoclonal antibody bidns pcsk9 wehrien sioalted monoclaoln antibody binsd epitope comprising least one residues 3 4 seq id no 5 wherein nmoolconal atnibdoy bolcks bnidnig pcsk9 ldlr 
Original summary:237 238 3 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:representative ant bodies hybridomas present invention deposited american col feb 28 200k assigned tlm access on numbers u table 3 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:separated monoclonal antibodies one wherein pcsk9 bonded to least residues dna sequence proposed seq id no 1 evenit general inhibition binding site monoclonal antibody reduces pcsk9 ldlr protein egfa domain antagonize ingestion cell induction ldl pcsk9 
Original summary:123 132 10 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody one wherein bound pcsk9 said monoclonal antibody binds least one residue within dna sequence set forth residues 123 132 seq id 1 wherein even said monoclonal antibody reduces binding sites pcsk9 also egfa domain ldlr protein antagonizes pcsk9 general inhibition cellular induced ldl uptake 
Original summary:123 132 10 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody inds pcsk9 iso at d antibody binps epitope comprising least one 3 4 seq id no 5 wherein antibody blocks 
Original summary:237 238 3 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:0115 pcsk9 antagonist antibody peptide aptamer exhibit one following tics a bind pcsk9 b block pcsk9 interaction ldlr c block decrease pcsk9 mediated down regula tion ldlr d inhibit pcsk9 mediated decrease ldl blood clearance e increase ldl clearance media cultured hepatocytes fj increase blood ldl clearance liver vivo g sensitize statins h block pcsk9 interaction yet identified factors 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:1 i 10 80 mg kg n 6 group dose response experiment male rats fed normal diet serum cholesterol levels dose dependently reduced maximum effect 50 seen 10 80 mg kg 48 hours post dosing 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:0149 adenoviruses eukaryotic dna viruses modified efficiently deliver nucleic acid inven tion variety cell types 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:large scale receptor ligand blocking screen screen antibodies block pcsk9 binding ldlr assay developed using d374y pcsk9 mutant 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:context antigen binding protein” protein made using recombinant techniques i e expression recombinant nucleic acid described herein 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated omnloconal antibody thta binds pcsk9 wherein isolated omnoclolna antibody binds epitope cpsk9 ocpmrisnig elast one residues 237 238 seq id no 3 wherein monoclonal antiobyd blocks binding pcs9k ldrl 
Original summary:237 238 3 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:ioslaetd monoclonal antibody hwerien bound pcs9k siad mnooclonal antbioyd binds least one residue within sequence set forth residues 544 582 seq id no 90 wherein asid mnoocolnal natbiody reduces binding pcsk9 egfa domain lldr protein antagonizes pcsk9 inhibition cellular ldl uptake 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:invention claimed monoclonal antibody model specifically physically binds k2 domain kunitz domain 2 tfpi one wherein said antibody line specifically binds epitope comprising residues e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 members seq id class 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:another separated monoclonal antibody wherein pcsk9 bonded monoclonal antibody binds least one following protein residues s153 i154 p155 r194 d238 possibly a239 i369 s372 may d374 perhaps c375 t377 c378 f379 v380 c378 f379 v380 c378 f379 v380 p s381 id no 10 wherein monoclonal antibody blocks pcsk9 ldlr binding 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 10 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:invention claimed is monoclonal antibody specifically binds kz domain kunitz domain 2 tfp1 whekein said antibody 8pecifica11y binds epitope comprising residues e10 b11 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:particular amino acid v» v sequences ihe germline sequences tn reduce risk antibody dna sequences human v» vc genes known art see e g human sequence database 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:i8o1ated monoclonal antibody binds pcsk9 wherein is01ated monoclonal antibody binds epitope pcsk9 comprising least one 0f kesidoes 237 z38 seq id no 3 whekein monoclonal antibody blocks binding pgsk9 ldlr 
Original summary:237 238 3 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody binds cpsk9 whernei siolaetd monoclonal antbidoy binds epitope pcsk9 ocmpirisng leats one residues 237 238 seq id no 3 ewhrein monoclonal antiobyd blocsk binding pcks9 ldlr 
Original summary:237 238 3 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:invention claimed monoclonal antibody specifically binds k2 domain kunitz domain 2 fragment tfpi wherein said antibody specifically specifically binds epitope comprising 6 residues e10 e11 d12 p13 r17 y19 t21 alternatively y23 f24 either n26 alternatively q28 q31 c32 e33 r34 k36 381 l50 seq id 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody candidate antigen specific binding fragment antibody specifically binds hpcsk9 comprising heavy chain complementarity determining region 1 named hcdr1 comprising amino acid sequence least 95 identical seq id 76 b heavy chain complementarity determining region 2 hcdr2 comprising amino acid sequence least 95 identical seq id 78 c heavy chain complementarity determining region 3 hcdr3 comprising amino acid sequence additional least 95 identical seq id 80 et light chain complementarity determining region 1 lcdr1 comprising amino acid sequence furthermore least 95 identical seq id 84 e light chain complementarity determining region 2 lcdr2 comprising amino acid sequence least 95 identical seq id 86 f new light chain complementarity determining region 3 lcdr3 additionally comprising amino acid sequence least 95 identical seq id 88 2 antibody antigen binding fragment antibody claim 1 wherein antibody antigen binding fragment antibody binds epitope comprising amino acid residue 238 hpcsk9 seq id 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:invention claimed is monoclonal antibody sepcifcilaly ibnds k2 domain uknitz domian 2 tfip wehreni siad antibody sepcifiaclly binds eiptoep ocmpriinsg residues e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:administration f l l3 resulted another additional 65 reduction ldl c addition 43 reduction zocor day 5 returned pre dosing levels within 2 weeks 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:separated rat monoclonal antibodies rat pcsk9 binding receptors wherein isolated monoclonal antibodies bind epitope pcsk9 comprises least one residue 277 278 seq id inlet no 8 wherein monoclonalanti antibody blocks binding pcsk9 receptor ldlr 
Original summary:277 278 8 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:invention claimed monoclonal antibody database specifically binds k2 domain kunitz domain 2 α tfpi wherein said given antibody specifically binds epitope comprising residues e10 regulatory e11 d12 subunit p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 element k36 l50 seq id 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:aspects invention comprises antigen binding protein selectively binds pcsk9 wherein antigen binding protein binds pcsk9 k smaller 100 pm 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:claimed is 1 isolated antibody wherein bound pcsk9 said monoclonal antibody binvds one residue sequence set forth residues 123 132 seq id no 1 said monoclonal antibody reduces betwe ekn pcsk9 egfa domain ldlr n antagonizes pcsk9 inhibition ldl uptake 
Original summary:123 132 1 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:embodiments antibodies bind variant least twice strongly wild type preferably 2 5 5 10 10 100 100 1000 1000 10 000 fold mutant wild type as measured via k 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:thus embodiments antigen binding proteins interact residues interact residues within 5 å residues contemplated provide useful inhibition pcsk9 binding ldlr 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibodies identified id05 suitable assays may tested ability antagonize neutralize i pcsk9 binding ldl tor and or ii pcsk9 internalization cells 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:0072 specific embodiments present invention pro vides isolated pcsk9 specific antagonists and spe cific embodiments antibody molecules comprising heavy chain variable region comprises seq id no 11 equivalents thereof characterized one con servative amino acid substitutions homologs thereof 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:pcsk9 antagonist antibodies peptidcs invention one more fol lowing characteristics a bind pcsk9 b block p 'sk9 uiteraction ldlr c decrease pcsk9 mediated down regulation lf lr d inhibit p 'sk9 medi ated inhibition i di blood clearance 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:since antibody responses protein antigens highly t cell dependent data presented application antibody production strongly suggest new compositions effective stimulating at least t helper cell mhc class ii restricted responses 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:making changes antigen binding protein pcsk9 protein according certain embodiments hydropathic index amino acids considered 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody binds monoclonal antibody binds epitope one residues 3 4 seq id no 5 wherein antibody blocks b pcsk9 ld9lr 
Original summary:237 238 3 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:typical vectors include plasmids modified viruses bacteriophage yeast artificial chromosomes bacterial artificial chromosomes forms episomal integrated dna 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody binds pcsk9 wherein isolated em onoclmonal a binds pcsk9 one residues 237 238 seq id no 3 wherein monoclonal blocks binding pacsk9 ldlrr 
Original summary:237 238 3 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:population studies shown pcsk9 mutations gain of function found individuals autosomal dominant hypercholes terolemia loss of function lof mutations linked reduced plasma cholesterol 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:certain embodiments even areas important biological activity structure subject conservative amino acid substitutions without destroying biological activity without adversely affecting polypeptide structure 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:invention claimed is monoclonal antibody specifically bind8 kz domain kunitz domain 2 tfpi wherein said antibody specifically binds epitupe comprising re8idue8 e10 e11 d12 p13 r17 y19 t21 y23 f24 n2b q28 q31 c32 e33 r34 k3b seq id no z 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:monoclonal antibody monoclonal antibody isolated combination pcsk9 monoclonal antibody least one mutual tracking residues s153 i154 mutants p155 r194 mutants d238 a239 i369 s372 mutant d374 seq id no c375 t377 c378 unit f379 v380 s381 cell 10 wherein monoclonal antibody blocks binding effect pcsk9 ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 10 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:mutagenesis germline sequences may carried using standard meth ods e g pcr mediated mutagenesis mutations incorporated pcr primers site directed 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:table 14 group dose quantity total animal formulation dna μg protein ha μg vehicle mg 6 1 10 ha 1 5 5 7 6 2 10 ova 1 5 5 7 6 3 10 ha 1 5 11 4 6 4 nil 1 5 5 7 6 5 10 nil 5 7 6 6 nil 1 5 nil pbs composition groups 6 1 6 2 dna protein coentrapped 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:n terminal c terminal naturally occurring light heavy chain variable regions typically following order elements fr1 cdr1 fr2 cdr2 fr3 cdr3 fr4 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:invention claimed is omnocolanl natibdoy htat specificlaly binds k2 doamin kunizt domain 2 ftpi wherein said naitbody specifiacyll binds pietope comprising residues e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:islotaed monoclonal antibody wherein bound pcsk9 monoclonal antibody binds laest one follonwig residues s153 i154 p155 r194 d238 2a39 i396 s372 d734 c375 t737 c378 f379 v380 s381 seq id no 3 wherein monoclonal antibody blocks bidnnig pcs9k ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:consider isolated human monoclonal antibody wherein bound pcsk9 monoclonal antibody ultimately binds least one following residues s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 seq serial id ii 10 wherein monoclonal antibody blocks binding pcsk9 express ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 10 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:table 6 dose 1 dose 2 dose 1 dose 2 entrapment entrapment size zeta size zeta group dna protein dna protein nm mv nm mv 2 1 79 8 71 3 90 5 88 9 379 18 1 nd 2 2 nil 30 3 nil 58 3 18 5 134 nd 2 3 85 6 nil 94 5 nil 367 19 1 nd nd determined 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:making changes based upon similar hydrophilicity values certain embodiments substitution amino acids whose hydrophilicity values within ±2 included certain embodiments within included certain embodiments within 5 included 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal anti60dy wherein bound pcskg said monoclonal antibody binds least one re8idoe within sequence set forth re8idoes 544 582 seq id no 9o wherein said monoclonal antibody redoce8 binding pcsk9 egfa domain ldlr protein antagonizes pcsk9 inhibition cellular ldl optake 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated onal antibody tha6t wherein isolated monoclonal body binds epitope pcsk9 com least one residues 237 238 seq id no 3 monoclonal antibody block s nding pcsk9 
Original summary:237 238 3 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:2000 july 81 pt 7 found provide protection influenza challenge absence antibody responses thus based cellular mediated immune response alone 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody specifically binsd hpcsk9 comprising a heavy chain complementarity region 1 hcdr1 comprising amino acid sequence least 95 identical seq id no 76 b heavy chain complementarity region 2 hcdr2 comprising amino acid sequence least 95 identical seq id no 78 c heavy chain complementarity determining region 3 hcdr3 comprising amino acid sequence least 95 identical seq id no 80 d light chain complementarity region 1 lcdr1 comprising amino acid sequence least 95 identical seq id no 84 e light chain complementarity determining region 2 lcdr2 comprising amino acid sequence least 95 identical seq id no 86 f light chani complementarity determining region 3 lcrd3 comprising amino acid sequence least 95 iednitcal seq id no 88 2 antibody antigen binding fragment antibody claim 1 wherein antibody antigen ibdning antibody ibnds epitope comprising amino acid residue 238 hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:specifically invention claimed monoclonal fluorescent antibody specifically binds k2 domain formerly kunitz domain 2 tfpi wherein said antibody molecule specifically intimately binds identified epitope comprising residues e10 e11 d12 p13 r17 y19 t21 protein y23 f24 n26 q28 q31 c32 e33 residues r34 k36 l50 products seq id 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:bead code separately incubated 100 ul 2 ug ml anti pcsk9 antibody coating antibody 1 hour washed 3× pbsa 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:degradation ldlr pcsk9 observed mechanism lowers extracellular ldlr protein levels 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:suitable peptide mimics group b polysaccharide g r molecular b epitopes 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:specific pcsk9 specific antagonists may carry detectable label may conjugated toxin e g radioactive radionuclide liposome targeting moiety biosensor cationic tail enzyme e g via bond linker 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:claimed is 1 antibody wherein bound pcsk9 said monoclonal antibody binds least one residue nce set forth 123 132 seq id no 1 wherein monoclonal antibody reduces binding pcsk9 domain ldlr protein pcsk9 inhibition cell ldl uptake 
Original summary:123 132 1 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:term fragment” refers polypeptide amino terminal deletion carboxyl terminal deletion and or internal deletion compared full length native protein 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:invention claimed monoclonal antibody technology specifically binds k2 domain kunitz domain level 2 tfpi wherein said antibody specifically weakly binds epitope comprising residues e10 e11 sometimes d12 otherwise p13 r17 y19 t21 y23 x f24 n26 q28 q31 c32 e33 r34 k36 l50 common seq id page 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:among them separated monoclonal antibodies combined pcsk9 monoclonal antibody binds least one sequences shown residues 123 132 seq id component no 1 andalso allow error monoclonal antibody reducing binding pcsk9 effective inhibition cell ldl egfa domain ldlr protein pcsk9 
Original summary:123 132 10 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:detailed description invention monoclonal antibody antibody specifically binds tfpi k2 domain kunitz domain 2 domain antibody specifically binds epitope residue e10 onlye11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 rather c32 e33 r34 k36 l50 seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:0093 present invention encompasses antibody mol ecules human humanized chimeric primatized 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:exemplary dosing regimen comprises ng dose 2 v maintenance dose ing kg thc pcsk9 antibody folio red dose every week 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:certain embodiments antibodies invention polyclonal monoclonal and or recombinant antibodies 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:specific embodiments provide isolated antagonists addition ally comprise heavy chain variable region cdri and or cdr2 sequences comprising seq id no 13 and or seq id no 15 respectively equivalents thereof characterized one conservative amino acid substitutions one cdr sequences 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody specifically binds hpcsk9 comprising a heavy chain complementarity determining region 1 hcdr1 comprising amino acid sequence least 95 identical seq id no 76 b heavy chain complementarity determining region 2 hcdr2 comprising amino acid sequence least 95 identical seq id no 78 c heavy chain complementarity region 3 hcdr3 comprising amino acid sequence least 95 identical seq id no 80 d light hcain determining region 1 lcdr1 comprising amino acid sequence least 95 identical seq id no 84 e light chain determining region 2 lcdr2 comprising aimno acid sequence least 95 identical seq id no 86 f light chain determining region 3 lcdr3 comprising amino caid sueqence least 95 identical seq id no 88 2 antibody antigen binding fragment antibody claim 1 wherein antiobyd antigen binding fragment antibody binsd epitope comprising amino acid residue 238 hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen fragment antibody specifically binds hpcsk9 comprising a chain complementarity determining region 1 hcdr1 comprising amino acid sequence least 95 identical seq id no 76 b chain complementarity determining region 2 hcdr2 comprising amino acid sequence least 95 identical seq id no 78 c heavy chain complementarity determining region 3 hcdr3 comprising amino acid sequence least 95 identical seq id no 80 d light chain complementarity region 1 lcdr1 comprising amino acid sequence least 95 identical seq id no 84 e light chain ko region 2 lcdr2 comprising amino acid ce least 95 identical seq id no 86 f light chaip complementarity determining region 3 lcdr3 comprising amino acid sequ pce least 95 identical seq id no 88 2 antibody antigen binding fragment antibody claim 1 wherein antibody antigen binding fragment antibody binds epitope comprising amino acid residue 238 hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:iosltaed monoclonal antibody binds pcs9k whreien isolated onmocloanl antibody binds epitope pcsk9 comprising lesat one resiudse 237 238 seq id no 3 wherein monolconal antibody blocsk ibndign pcsk9 dllr 
Original summary:237 238 3 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isotlaed monoclonal antibody wherein boudn pcsk9 asid monoclonal antibody binds leats one residue within sequence set forth residues 544 582 seq id no 90 wherein asid monoclonal antibody reduces binding pcsk9 egfa domain lldr protein antagonizes pcsk9 inhbitioin ecllulra ldl uptkae 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:invention claimed product monoclonal antigen antibody candidate specifically binds linked k2 domain kunitz domain 2 tfpi wherein said antibody specifically specifically binds epitope comprising residues e10 e11 e d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 drug seq id 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:5 å chosen core region cutoff distance allow atoms within van der waals radius plus possible water mediated hydrogen bond 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:0134 specific embodiments herein provide pharmaceuti cal compositions described comprise 50 200 mg ml one various pcsk9 specific antagonists described herein 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:i'he nucleic acid aptamer double stranded dna single rna nucleic acid uiclude moditied bases functional groups uicluding limited nucleotides methyl nucle include hydrophilic polymers 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:specific embodi ments present invention provides homologs dis closed antagonists characterized least 90'zo iden tical cdr3 sequences within cdri cdr2 cdr3 sequences seq id no 17 seq id nos 13 15 17 respectively appropriate said antago nists inhibit human and or murine pcsk9 dependent inhibition cellular ldl uptake least 10'zo 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal anti60dy binds pcsk9 wherein isolated monoclonal antibody binds epitope pcsk9 cumpri8in9 least one uf residues 237 ok 238 seq 1d no 3 wherein monoclonal antibody blocks 6indin9 pcsk9 ldlr 
Original summary:237 238 3 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:usia ihe gene sequence express antibody recombinantly host cells e g ho cells another method mny bc express antibody sequence n plants e g tobacco milk 
Original summary:no data 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:similarly isolated monoclonal antibody strongly bonded pcsk9 wherein isolated monoclonal antibody binds antibody epitope plurality pcsk9 receptors comprises relatively least least residue 277 278 domain seq id no 8 one wherein monoclonal individual antibody block binding pcsk9 linked ldlr 
Original summary:277 278 8 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antiobyd antigen binding fragment natibdoy specifically binds hpcsk9 comprising a hevay chain complementarity determining region 1 hcdr1 comprising amino acid sequence htat least 95 identical seq id no 76 b heavy chain complementarity determining regoin 2 hcdr2 ocmprsiign amino acid sequence least 95 identical seq id no 78 c heavy chain complementarity determining region 3 hcdr3 comprising amino acid sequence least 95 identical seq id no 80 d ligth chain complementarity determining region 1 lcdr1 comprising aimno acid sequence least 95 identical seq id no 84 e light chian complementarity determining region 2 lcdr2 comprising amino acid sequence least 95 identical seq id no 86 f light chain complementarity determining region 3 lcdr3 comprising amino acid sequence least 95 identical seq id no 88 2 antiobyd antigen binding fragment antibody claim 1 wherein antibody antigen binding fragment antibody binds epitope comprising amino acid residue 238 hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody pcsk9 antibody binds least one following s153 i154 p155 r194 i369 s372 c375 c378 f379 v380 s381 seq id no 3 wherein monoclonal blocks binding pcsk9 ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:general theory general theory states enhanced performance appropriately co formulated material wherein dna cognate protein associated single vesicle vesicles population dna protein due acquisition nucleic acid cognate protein the assistor protein antigen presenting cell be classical antigen presenting cell dendritic cell b cell antigen specific non antigen specific 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:competition binding members may readily assayed vitro example using elisa and or interaction antibodies pcsk9 solu tion 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:0140 pcsk9 specific antagonist may adminis tered individual route administration appre ciated art including limited oral administra tion administration injection specific embodiments include intravenous subcutaneous intraperitoneal intramuscular injection administration inhalation intra nasal topical administration either alone combina tion agents designed treatment individual 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:n 2 2 2 2 2 3 bis octadec 9 enyloxy propoxy ethoxy ethoxy ethoxy ethyl 3 3 4 5 trihydroxy 6 hydroxymethyl tetrahydro pyran 2 ylsulfanyl propionamide given dogp4αman kind gift dr louis strasbourg i de 74 route du bp 24 
Original summary:no data 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:one embodiment antibody administered formulation sterile aqueous solution ph ranges 5 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:invention is antibody hinds k2 domain kunitz domain 2 tfpo said antihory cally binds epitope e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:animal isolated characterized monoclonal antibody wherein bound pcsk9 said monoclonal antibody binds least one residue within sequence set forth residues 544 582 seq id 90 wherein said monoclonal antibody reduces factor binding pcsk9 egfa domain target ldlr g protein antagonizes pcsk9 inhibition cellular ldl uptake 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:independent antibody antigen binding fragment industrial antibody specific binds hpcsk9 including a heavy chain complementary determination region 1 hcdr1 comprising amino acid sequence least 95 76 b seq id no chain complementary determination region 2 hcdr2 contains amino acid sequence least 95 seq id no 78 c heavy chain complementary determination region 3 hcdr3 containing amino acid sequence associated seq idno 80 least 95 d light chain complementary determination region 1 lcdr1 comprising amino acid sequence least 95 seq id no 84 e light chain complementary determinationregion 2 lcdr2 comprises amino acid sequence least 95 seq id no 86 f light chain complementary determination region 3 lcdr3 containing amino acid sequence associated seq id no 88at least 95 2 a particular antibody antigen binding fragment antibody according claim 1 wherein antigen binding fragment antibody antibody binds epitope amino acid residue 238 comprising hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:oral immunoglobului wn sulfate precipitation gel electro 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody binds pcsk9 wherein isolated monoclonal antibody binds epitope comprising least one version residues 3 part 4 seq id element 5 wherein independent monoclonal antibody blocks binding pcsk9 binding host ldlr 
Original summary:237 238 3 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:understood remaining section light heavy chain shown base abp 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:immunization host animal human pcsk9 fragment con taining target amino acid sequence conjugated protein species immunized e g keyhole limpet serum albumin bovine thyro globulin soybean trypsin inhibitor using bifunctional agent example ester conjugation cysteine residues n hy through lysine residues glutaraldehyde succinic anhydride r'n c nr r r' different alkyl groups yield population anti bodies e g monoclonal antibodies 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody binds pcsk9 wherein i8ulated monoclonal antibody binds epitope pcsk9 comprising least one re8idue8 237 ok 238 uf seq 1d nu 3 wherein m0noc10nal anti60dy blocks 6indin9 pcsk9 ldlr 
Original summary:237 238 3 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal u antibody resulting monoclonal antibody binds least one following residues pcsk9 bonded s153 i154 p155 r194 d238 a239 i369 s372 d374 c375the t377 c378 f379 v380 m1 s381 c375 seq id database no 10 wherein monoclonal ii antibody blocks binding target pcsk9 ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 10 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:embodiments statin selected group consisting atorvastatin cerivastatin fluvastatin lovastatin mevastatin pitavastatin pravastatin rosuvastatin simvastatin combination thereof 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:hwat claimed is 1 iosltaed monoclonal antibody whreeni bound cpsk9 said monoclonal antibody binds least one residue within sequence set fotrh residues 123 132 seq id no 1 wherein sadi mnoocloaln antibody reduces binding pcsk9 egfa domain ldlr protein antagonizes pcs9k inhibition cellular ldl putake 
Original summary:123 132 1 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:certified binding chemistry 96 well plates coated overnight 50 μl well influenza ha pr8 antigen 20 μg ml pbs 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody wherein bound pcsk9 monuc1ona1 antibody binds least one following kesidue8 s153 i154 p155 r194 d238 a239 i369 s372 d371 c375 t377 f379 v380 s381 seq id no 3 wherein monoclonal antibody blocks 6indin9 pcsk9 tu ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:binds pcsk9 isolated dy binds epit pc comprising least one residues 3 4 seq id no 5 monoclonal antibody blocks pcsk9 ldcr 
Original summary:237 238 3 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:specifically isolated monoclonal antigen antibody wherein bound substrate pcsk9 said monoclonal antibody binds least one residue within sequence set forth residues 123 residue 132 seq fragment id 1 wherein said monoclonal antibody reduces binding affinity pcsk9 egfa domain serum ldlr protein antagonizes pcsk9 inhibition cellular ldl uptake 
Original summary:123 132 10 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:pc'sk9 sts herein compositions well them also described mi below 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:variant fc region comprises amino acid sequence differs native sequence fc region least one amino acid modification yet retains least one effector function native sequence fc region 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:purification processes may involve filtration passage porous membrane defined pore size gel exclusion chromatography size exclusion chromatography vesicles appear volume 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:embodiments binding affinity less 250 nm 200 nm 100 nm 50 nm 10 nm nm 500 pm 100 pm 50 pm 20 pm 10 pm 5 pm 2 pm 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:monoclonal antibody wherein bound pcsk9 monoclonal antibody least one following residues s153 i154 p155 d238 a239 s372 d37 4 c375 t377 c378 v380 s381 seq id no 3 monoclonal ant ibody blocks binding ldlrr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody wherein bound pcsk9 said monoclonal antibody binds least one residue within sequence set forth residues 123 residues 132 seq id 1 5 wherein said monoclonal cancer antibody reduces binding pcsk9 egfa domain ldlr protein antagonizes pcsk9 inhibition rate cellular ldl mrna uptake 
Original summary:123 132 10 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:improvement exhibited present invention involves composition liposome forming materials and associated liposomes nucleic acid operatively encoding antigenic protein co delivered protein wherein co delivered protein shares epitopes antigenic protein 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal ody binds pcgsk9 wherein ated a ntib ody binds comprising least one residues 3 4 seq id no 5 wherein monoclonal ant binding kpcsk9 ldl5r 
Original summary:237 238 3 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody wherein bound pcsk9 mogocl na antibody binds oeast one following residues s153 i154 r194 dq38 a239 i369 d3i4 c375 t377 c3u8 f379 v380 s381 seq id no 3 wherein blofks binding pcsk9 ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:another embodiment invention provides antibody comprising specific vl cdri cdr2 and or cdr3 sequences variant thereof one conservative amino acid substitutions cdri cdr2 and cdr3 comprising vh complementary deter mining region cdri amino acid sequence shown seq idno 59 60 8 amino acid sequence shown seq id no 61 9 and or vh cdr3 amino acid sequence shown seq id no 10 variant thereof one conservative amino acid substitutions said sequences cdri cdr2 and or cdr3 wherein variant retains essentially bind ing specificity cdri cdr2 and or cdr3 defined said sequences 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding antibody specifically binds hpcsk9 a heavy complementarity determining region 1 hcdr1 comprising amino acid sequence least 95 identical seq id no 76 b heavy chain complementarity determining region 2 hcdr2 comprising amino acid sequence least 95 identical seq id no 78 c hea chain complementarity determining region 3 hcdr3 comprising amino acid sequence least 95 identical seq id no 80 d light chain complementarity determining region 1 lcdr1 comprising amino acid sequence 95 identical seq id no 84 e light chain complementarity determining region 2 lcdr2 comprising amino acid sequence least 95 identical seq id no 86 f light chain complementarity determining region 3 comprising amino acid least 95 identical seq id no 88 2 ody antigen binding fragment antibody claim 1 antibody antigen binding fragment antibody binds epitope comprising amino acid residue 238 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:b pcsk9 antagonists 0114 methods invention use pcsk9 antago nist antibody peptide aptamer refers peptide nucleic acid molecule blocks suppresses reduces us 2010 0068199 a1 mar 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal protein antibody wherein initially bound pcsk9 said monoclonal antibody binds least one residue within sequence set drawn forth residues 544 582 seq id series 90 2012 wherein said monoclonal antibody reduces binding pcsk9 via egfa repeat domain ldlr protein antagonizes pcsk9 inhibition cellular ldl gene uptake 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen fragment antibody specifically binds hpcsk9 comprising a heavy vhain complementarity determining region 1 hcdr1 comprising amino acid sequence least 95 identical seq id no 76 b heavy chain complementarity determining region 2 hcdr2 comprising amino acid sequence least 95 identical seq id no 78 c heavy chain complementarity determining region 3 hcdr3 comprising amino asid sequence least 95 seq id no 80 d light chxin complementarity determining region 1 lcdr1 amino acid sequence least 95 identical seq id no 84 e light chain complementarity determining region 2 lcdr2 comprising amino acid sequence least 95 identical seq id no 86 f light chain cp determining region 3 lcdr3 c amino acid sequence l ast 95 identical seq id no 88 2 antibody antigen binding fragment antibody claim 1 wherein antibody antigen binding fragment antibody binds epitope comprising amino acid residue 238 hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody wherein bound pcsk9 monoclonal binds leas t one following residues s153 i154 p155 r194 d238 d374 t377 c37 8 f379 v380 s381 seq id no 3 wherein monoclonal antibody blocks 8pcsk9 ludlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:examples antigen binding molecules include peptibodies small molecules polymers modified egfa increase affinity pcsk9 and or half life mutation amino acids glycosylation pegylation fc fusions fusions 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:light chain residues within 5 8 angstroms pcsk9 include following s26 n55 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:specific embodiments present invention comprising nucleic acid encoding disclosed pcsk9 specific antagonists include limited to e coli see e g pluckthun 1991 bio 9 545 551 yeast pi a recombinant derivatives thereof see e g li et al 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:aptamers nucleic acid peptide molecules capable selectively binding target molecule one specific example 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:invention claimed identifying mixed monoclonal antibody specifically binds within k2 antigen domain kunitz domain 2 tfpi wherein said antibody specifically binds towards epitope comprising residues e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 type q31 c32 e33 r34 k36 l50 residue aids seq id 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody wherein externally bound pcsk9 whenever said viral monoclonal antibody binds directly least one residue within sequence set forth residues 123 residues 132 seq id 1 wherein said monoclonal antibody reduces binding individual pcsk9 egfa domain ldlr protein antagonizes pcsk9 subsequent inhibition cellular ldl uptake 
Original summary:123 132 10 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:used herein terms refers incorporation detectable marker e g incorporation amino acid attachment polypeptide biotin moieties detected marked avidin e g streptavidin containing fluorescent marker enzymatic activity detected optical colorimetric methods 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:claimed is monoclonal binds k2 domain munitz domaun 2 tfpi said specifically binds comp e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:exemplary effector functions include clq binding complement depen dent cytotoxicity fc receptor binding antibody dependent cell mediated cytotoxicity down regulation cell surface receptors e g b cell receptor etc 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:hbs p buffer ph 7 4 0 01 hepes 0 15 nacl 0 005 surfactant p 20 biacore supplemented 0 01 bsa used binding buffer 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:preferably host cells express cdnas level 5 fold higher preferably 10 fold higher even preferably 20 fold higher corresponding endogenous antibody protein interest present host cells 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:5 399 4 650 4 980 5 124 mann et al cell 33 153 1983 et al j vi 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody specifically binds hpcsk9 comprising a heavy complementarity determining region 1 hcdr1 comprising amino acid sequence 95 identical seq id no 76 b heavy chain complementarity determining region 2 hcdr2 comprising amino acid sequence least 95 identical seq id no 78 c heavy chain complementarity determining region 3 hcdr3 comprising amino acid sequence least 95 identical seq id no 80 d light complementarity determining region 1 lcdr1 comprising qmino acid sequence least 95 identical seq id no 84 e light chain complementarity determining region 2 lcdr2 comprising amino acid sequence least 95 seq id no 86 f light chain complementarity determining region 3 lcdr3 comprising amino acid sequence tbat least 95 identical seq id no 88 2 antibody antigen fragment claim 1 wherein antibody antigen binding ir gment antibody binds epitope comprising amino acid residue 238 hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:variety individual mutants obtained collected binding results analyzed determine residues affect binding 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:13a 13 c 13 f 13 g defined based upon hybrid combination chothia method based location structural loop regions see e g canonical structures immunoglobulins ” al lazikani m chothia molecular biology 273 4 927 948 7 1997 kabat method based sequence variability see e g sequences proteins immunological interest fifth edition 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:i8ulated monoclonal antibody binds pcsk9 wherein i8o1ated m0noc1ona1 antibody binds epitope comprising least one re8idue8 3 0r 4 seq id no 5 wherein monoclonal antibody blocks 6indin9 uf pcsk9 ldlr 
Original summary:237 238 3 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:3 e 3 depict amino acid nucleic acid sequences variable domains embodiments antigen binding proteins 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:embodiments antigen binding protein comprises and or consists 1 2 and or 3 heavy and or light cdrs least one sequences listed table 2 cdrs sequences outlined figs 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:1 vcsk9 antagonist provided bc el 1 onist at essentially completely blocks measurable effect pcsk9 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:inventnio n d is monoclonal antibody that specifically k2 domain 2 tfpi sa id specifically binds epitope comprising residues e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody hwerien bound psck9 said monoclonal antibody binsd laest one reisdeu wihtin sequence set forth residues 544 582 seq id no 90 wherein said monoclonal antibody reduces binding pcsk9 efga domain ldlr ptroein antagonizes pcsk9 inhibition cellualr ldl utpake 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:forest atcc vr 67 atcc vr 1247 ross river virus vr 373 atcc vr 1246 equine encephalitis atcc vr 923 atcc v r 1250 vr 1249 atcc vr 532 adeno associated virus aav vectors see e g pct publ 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:invention claimed monoclonal antibody specifically also binds residues k2 domain kunitz domain 2 members tfpi b wherein said antibody also specifically binds epitope comprising residues e10 e11 d12 p13 r17 y19 t21 f y23 f24 n26 q28 q31 r c32 te e33 e r34 k36 l50 member seq id 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated omncoloanl antibody wherein buond pcsk9 monoclonal anitboyd binds least one following residues s153 i154 p155 r194 d238 a293 i369 s372 d374 c375 t377 c387 f397 v308 s381 seq id no 3 hwerien monoclonal antibody blocks binding pcsk9 ldrl 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:physician able select appropriate treatment target lipid levels depending individual profile particular patient 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated synthetic monoclonal antibody wherein possibly bound pcsk9 often monoclonal antibody binds least one last following residues s153 i154 p155 r194 d238 protein a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 seq id group 3 wherein monoclonal antibody blocks possible binding pcsk9 ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:one example anti ui body comprismg light chain human heavv clmin mitibodies bc using ven ous art 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:invention claimed proposed monoclonal antibody specifically binds long k2 domain kunitz domain type 2 tfpi wherein said antibody specifically binds epitope comprising residues e10 peptide e11 d12 p13 r17 y19 peptide t21 y23 f24 n26 sequence q28 q31 c32 e33 r34 k36 another l50 member seq id 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:least 95 dent ty polynucle otide sequence encodes nat ve antibody portion thereof tivo polynucleot de polypepude sequences sa d identical sequence des o acids tivo aligned correspondence descnbed 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:islotaed mnoolcoanl antibody bnids pcs9k wherein isolated omnoclonal antibody binds epiotep cormpsiing leats one residues 3 4 seq id no 5 whreein monoclonal antibody blokcs binding pcsk9 ldlr 
Original summary:237 238 3 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:certain embodiments view condition desired level treatment two three agents administered 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:six groups 8 week old c57 b16 mice n 8 group bled tested cholesterol levels day — 7 administered indicated doses antibodies saline days 0 i 2 3 i p bolus injection 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:preferred method determining ko binding molecule using surface plasmon resonance example employing biosensor system ge healthcare life sciences system 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody specifically successfully binds hpcsk9 comprising heavy chain complementarity determining region 1 hcdr1 comprising amino acid sequence least 95 identical seq id 76 b heavy chain complementarity determining region 2 hcdr2 comprising amino acid sequence least 95 identical seq id 78 c heavy chain complementarity determining region 3 hcdr3 comprising amino acid sequence least 95 identical seq id 80 light chain complementarity determining region 1 lcdr1 comprising amino acid sequence least 95 identical seq id 84 e light chain complementarity determining region 2 lcdr2 comprising amino acid sequence least 95 identical seq id 86 f new light chain complementarity indicator determining region 3 lcdr3 comprising amino acid sequence least 95 identical seq id 88 2 antibody antigen binding fragment antibody claim 1 wherein antibody antigen binding fragment antibody binds antibody epitope comprising amino acid residue 238 north hpcsk9 seq id 279 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody specifically strongly binds hpcsk9 comprising heavy chain complementarity determining region 1 hcdr1 comprising amino acid primary sequence least 95 identical seq id 57 76 b heavy chain complementarity determining region 2 hcdr2 comprising amino acid sequence least 95 identical seq id 78 c heavy chain complementarity determining region 3 hcdr3 comprising amino acid sequence least 95 identical seq id 80 light chain complementarity determining region 1 lcdr1 comprising amino acid sequence least 95 identical seq id 84 e light chain complementarity determining region 2 lcdr2 comprising amino acid sequence broadly least 95 identical seq id 86 f determined light chain complementarity determining region 3 lcdr3 comprising amino acid secondary sequence least 95 identical seq id 88 2 antibody antigen binding fragment antibody claim 1 wherein antibody antigen binding fragment antibody binds epitope comprising amino acid residue 238 hpcsk9 seq id 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:constant region may aglycosylated n linked glycosylation cally expression glycosylation deficient host cell 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody wherein combined pcsk9 monoclonal antibody least one residue sequence residue 123 residue 132 id no 1 5 least one residue 132 combined monoclonal cancer antibodies reduced binding pcsk9 egfa domain ldlr proteins antagonized inception inhibition pcsk9 cell ldl mrna 
Original summary:123 132 10 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody specifically binds hpcsk9 comprising a heavy chain complementarity determining region 1 hcdr1 comprising amino acid sequence least 95 identica1 seq id no 76 b heavy chain complementarity determining region 2 hcdr2 comprising amino acid sequence least 95 identical seq id no 78 c heavy chain complementarity determining region 3 hcdr3 comprising amino acid sequence least 95 identical seq id no 80 d light chain complementarity determining region 1 lcdr1 c0mpki8ing amino acid sequence least 95 identical seq id no 84 e light chain determining region 2 lcdr2 comprising amino acid sequence least 95 identical seq id no 86 f light chain complementarity determining 3 lcdr3 comprising amino acid sequence least 95 identical seq id no 88 2 antibody antigen binding fragment antibody claim 1 wherein antibody antigen binding fragment antibody binds epitope comprising amino acid residue 238 hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:presently requested is monoclonal antibody specifically binds k2 domain tfpi kunitz domain 2 wherein antibody specific binding comprises protein residues e10 e11 d12 p13 the epitope y23 f24 n26 q28 q31 c32 residues e33 r34 k36 seq id no p 2 l50 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:carboxy terminal portion chain typically constant region responsible effector function 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:embodiments antigen binding protein comprises a polypeptide structure b one cdrs inserted and or joined polypeptide structure 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:invnetino lciamed is omnolcnoal antibody espcificalyl binds k2 dmoain kunitz domani 2 tfip whreien said antibody specifically binds epitope cmopirsign rseideus e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding signal fragment specifically binding hpcsk9 antibody comprises a comprising heavy chain complementary determination region 1 hcdr1 heavy chain complementary determination region 1 hcdr1 comprises amino acid sequence amino acid sequence least 95 76 b heavy chain complementary determination region 2 hcdr2 contains amino acid sequence least 95 seq id no 78 c heavy chain complementary determination region 3 hcdr3 comprising complete amino acid sequence least 95 seq id no 80 d light chain complementary determination region 1 lcdr1 comprises amino acid sequence least 95 seq id no 84 e light chain complementary determination region 2 lcdr2 comprising amino acid sequence least 95 seq id no 86 f light chain complementary determination region 3 lcdr3 contains least 95 amino acid sequence seq id no 88 antibody antigen binding fragment claim 1 wherein antibody antigen binding fragment antibody binds epitope amino acid residue 238 comprising hpcsk9 as seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:is 1 ted monoclonal antibody wherein bound pcsk9 said monoclonal antibody binds least one sequence set forth 123 132 seq id no 1 wherein said monoclonal binding pcsk9 egfa ldlr antagonizes inhibition cellular ldl uptake 
Original summary:123 132 1 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody wherein bound collectively pcsk9 typically monoclonal antibody binds least one following residues normal s153 i154 p155 normal r194 d238 a239 i369 serum s372 d374 human c375 t377 c378 f379 v380 s381 seq id element 3 wherein monoclonal antibody blocks binding pcsk9 ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:claimed is 1 isolated monoclonal antibody wherein obund cpsk9 asid monoclonal antibody binds least one residue within sequence set forth residues 123 132 seq id no 1 wherein asid omnocnloal antibody reduces bnidign pcks9 egfa domian dllr protein antagonizes pcsk9 inhibition cellular ldl upatke 
Original summary:123 132 1 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:certain embodiments compositions administered bolus injection infusion implantation device 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:certain exemplary activities functions molecule include limited to binding affinity enzymatic activity signal transduction 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:thc pcsk9 refers vanants ai least part activity pcsk9 unless indicated differently spccilic human pcsk9 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody specifically binds hpcsk9 comprising heavy chain complementarity determining region 1 hcdr1 comprising amino acid sequence least 95 identical seq id 76 b heavy chain complementarity determining region 2 hcdr2 comprising amino acid sequence least 95 identical seq id 78 c heavy chain complementarity determining region 3 hcdr3 comprising amino acid sequence least 95 identical seq id 80 within light chain complementarity determining region 1 lcdr1 comprising amino acid sequence least 95 identical seq id 84 e light chain complementarity determining region 2 lcdr2 comprising amino acid sequence least 95 identical seq id 86 f light chain complementarity determining region 3 specifically lcdr3 comprising amino aromatic acid sequence least 95 identical seq abd id 88 2 antibody antigen binding fragment antibody claim 1 wherein antibody antigen binding fragment antibody binds epitope comprising amino amino acid residue 238 hpcsk9 seq id 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:certain embodiments antigen binding protein pcsk9 administered concurrent administration least one therapeutic agent 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment type antibody specifically binds hpcsk9 comprising heavy chain complementarity determining region 1 hcdr1 comprising amino acid sequence least 95 identical seq id 76 b heavy chain complementarity determining region 2 hcdr2 comprising amino acid sequence least 95 identical seq id 78 c heavy chain complementarity determining region 3 hcdr3 comprising amino acid sequence generally least least 95 identical seq id 80 light chain complementarity determining region 1 lcdr1 comprising amino acid sequence least 95 identical seq id 84 e light chain complementarity determining region 2 lcdr2 comprising amino acid sequence least 95 identical relative seq id 86 f light chain independent complementarity determining region 3 lcdr3 comprising amino acid sequence least 95 identical seq id 88 2 antibody antigen binding fragment antibody claim 1 wherein antibody antigen binding protein fragment antibody binds epitope comprising amino acid residue № 238 hpcsk9 seq id 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:method affinity human antibodies obtained phage display improved sequentially replacing heavy light chain v region genes repertoires naturally occurring vari ants repertoires v domain genes obtained donors 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody wherein viral monoclonal antibody directly engaged pcsk9 time viral monoclonal antibody directly seq id no 1 residues 123 residue 132 residues 123 sequence residues 132 directly bonded least one residue the monoclonal antibody reduces binding individual pcsk9 egfa domain ldlr protein antagonize subsequent inhibition cell ldl pcsk9 
Original summary:123 132 10 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:general techniques 0058 practice present invention employ unless otherwise indicated conventional techniques molecular biology including recombinant techniques cell biology immunology within skill art 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:hwat claimed is 1 isoaltde monoclonal antibody wherein obund psck9 said monoclonal antibody binds least one resuide within sequence set fotrh residues 123 132 seq id no 1 weherin said monoclonal antbioyd reduces binding bewtene pcsk9 egfa domain dllr protein antagonizes pcsk9 inhibition cellular ldl uptake 
Original summary:123 132 1 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:embodiments antibody comprises constant region igg4 comprising following mutations et al 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated binds wherein monoclonal antibody binds pcskg least one residues 237 238 seq id no 3 monoclonal blocks binding ldlr 
Original summary:237 238 3 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal ahtivody bindx pcdk9 wherein isolated monoclonal antibody vinds epi pcsj9 cp prisiny least one resid 237 238 seq id no 3 wherein antibody blockz binding pcsk9 ldlr 
Original summary:237 238 3 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:monoclonal anti binds pcsk9 wherein monoclonal binwds pcsk9 comprising one dues 237 238 seq id no 3 wh e rein monoclonal body blocks binding pcsk9 ldlr 
Original summary:237 238 3 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody wherein bound pcsk9 m0noc1ona1 antibody binds least one following residues s753 i154 p155 r194 0238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s3 1 8eq id no 3 wherein m0noc1ona1 antibody blocks binding pcsk9 ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:thus assistor protein provide additional cytotoxic t cell responses i e increase concentration and or duration expression mhc class ii restricted peptide epitopes antigen recognized t helper cells surface antigen presenting cell increasing t cell cytotoxic t cell responses expressed form protein antigen presented via class i mhc pathway 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:entirely isolated monoclonal antibody complex specifically binds pcsk9 wherein isolated monoclonal antibody binds epitope found host pcsk9 comprising least one pair residues 277 278 manufacturer seq id 8 wherein intermediate monoclonal antibody blocks binding pcsk9 ldlr 
Original summary:277 278 8 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen b ndihg fragment tmat specifically binds hpcsk9 comprising a heavy chain complementarity determining region 1 hcdr1 comprising amino acid sequence least 95 identical seq id no 76 b heavy chain c determining region 2 hcdr2 comprising amino acid sequence least 95 seq id no 78 c heavy chain complementarity determining region 3 hcdr3 comprising amino acid sequence least 95 identical seq id no 80 d light chain complementarity determining region 1 lcdr1 amino acid sequence least 95 identical seq id no 84 e light chain complementarity determining region 2 lcdr2 comprising amino sequence 95 identical seq id no 86 f light chain c determining region 3 lcdr3 comprising amino acid sequence least 95 identical seq id no 88 2 antibody antigen binding fragment antibody claim 1 wherein antkbory antigen binding fragment antibody binds epitope comprising amino acid residue 238 hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody specifically intimately binds hpcsk9 comprising heavy three chain complementarity determining region 1 hcdr1 comprising amino acid sequence least 95 identical according seq id 76 b heavy chain complementarity determining region 2 hcdr2 commonly comprising amino acid sequence least 95 identical seq id 78 c main heavy chain complementarity determining region 3 hcdr3 comprising amino acid sequence least 95 identical seq id 80 light chain complementarity determining region 1 lcdr1 comprising amino acid sequence least 95 identical seq id 84 e light chain complementarity determining region 2 lcdr2 comprising amino acid sequence least 95 identical seq id 86 f short light chain complementarity determining region 3 lcdr3 comprising amino acid sequence least 95 substantially identical seq id 88 2 antibody antigen binding fragment antibody claim list 1 wherein antibody antigen binding fragment antibody binds epitope comprising amino acid residue 238 hpcsk9 seq id 34 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:invention cailmed is mnocoolnal antibody spceifically binds k2 odmain kunizt domain 2 tfpi hweerin asid anbtiody specifically binds eptipoe coprmisnig residues e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:another method may employed express antibody sequence plants e g tobacco transgenic milk 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:best results achieved liposomes include lipids usually phosphatidyl ethanolamines acyl groups unsaturated 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody molecule selective pcsk9 comprises vl comprising seq id no 27 vh comprising seq id no 11 shown decrease binding id05 antibody molecule likely peptide id05 bind same closely related epitope 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:full length antibodies desired sequence avail able human heavy chain constant region genes see e g kabat 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:n 0 um chloride sodium ci rate 50' a 55' followed high wash cons g » o containing 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated antibody wherein ound pcsk9 saie monoclonal antibody binds least one within set forth 544 582 seq id no 90 wherein snid monoclonal antibody reduces binding ed pcsk9 egfa domain protein antagonizes pcsk9 inhibition cellular ldl uptare 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:invention claimed is antibody f cally binds k2 kunitz domain 2 xaid specifically bindd residues e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:finally 40 μl well one step tmb neogen lexington ky added plate quenched 40 μl well 1n hydrochloric acid 30 minutes room temperature 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:wells treated blocking agent milk protein albumin prevent nonspecific adsorption analyte 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:whta claimed is 1 isolated monoclonal atnibdoy wherein bound cpsk9 said monoclonal antboidy binds least one residue within sequneec set forth residues 123 132 seq id no 1 wherein said omnolcoanl antibody reduces binding beteewn pcsk9 gefa odmain ldlr protein antagonizes pcsk9 inhibition cellular ldl utpake 
Original summary:123 132 1 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:embodiments abp administered subject statin order determine statin increased amount pcsk9 subject 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:i8o1ated monoclonal antibody binds pcsk9 wherein i8o1ated monoclonal anti60dy binds epitope pcsk9 c0mpri8in9 least one residues 237 238 uf seq id no 3 wherein monoclonal antibody blocks binding uf pgsk9 l0lr 
Original summary:237 238 3 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:suitable expression vectors include limited plasmids viral vectors including adenoviruses adeno associated viruses ruses expression vector s disclosed pct publ 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:term pcsk9 also encompasses pcsk9 molecules incorporating post translational modifications pcsk9 amino acid sequence pcsk9 sequences glycosylated pegylated pcsk9 sequences signal sequence cleaved pcsk9 sequence pro domain cleaved catalytic domain separated catalytic domain e g figs 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:difference be example different purity found nature different structure form part different structure found nature 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody wherein strongly bound pcsk9 monoclonal antibody binds least one following residues s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 seq id number 10 wherein monoclonal antibody antibody blocks binding pcsk9 ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 10 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:utilizes isolated monoclonal antibody binds pcsk9 wherein multiple isolated monoclonal antibody binds epitope pcsk9 comprising least one residues 237 238 seq id 3 wherein alternatively monoclonal injection antibody blocks prior binding events pcsk9 ldlr 
Original summary:237 238 3 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:one embodiment antibody phage library tlmt phage library expresses human mitibodies et nl 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:case multiple wild type controls conservative approach taken wild type control similar mutant i e ones largest p values 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:preferred embodiments compositions wherein r1 r2 individually 0 6 sites structure ch 3 — ch 2 — 2 b — ch 2 c — wherein sum c 1 23 b 0 6 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated human monoclonal antibody loosely coupled pcsk9 wherein isolated monoclonal antibody may bonded epitope pcsk9 comprises least least residue 277 278 seq id no 8 one wherein pcsk9 molecule ldlr binding blocks 
Original summary:277 278 8 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:i claimed is monoclonal antibody tha specifically bknds k2 eomain kunitz domain 2 wher 0n saik antibody binds residues e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:0153 sindbis virus member alphavirus genus studied extensively since discovery various parts 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:certain embodiments pharmaceutical compositions include one different antigen binding protein pcsk9 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:wherein isolated monoclonal human antibody wherein bound pcsk9 said small monoclonal antibody binds least one recognition residue within sequence set forth residues 123 132 seq site id 1 wherein said monoclonal antibody partially reduces binding adjacent pcsk9 utilizes egfa domain ldlr protein antagonizes pcsk9 inhibition cellular ldl uptake 
Original summary:123 132 10 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal binds pcsk9 monoclonal binds comprising one 3 4 seq id no 5 wherein monoclonal antibody blo ks pcskw ldlr 
Original summary:237 238 3 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:mice received two doses days 0 28 sample bleeds collected tail vein day 21 post 1 dose 42 post 2 doses respect first injection 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:invention claimed is antibody specifically binds k2 tz domain 2 wherein said a ally bhinds e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:resulting collected media sample hybridoma line spun remove cells debris 15 minutes 3000 rpm resulting supernatants filtered 0 22 pm 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:consensus sequences determined keeping cdrs contiguous within sequence corresponding v h v l 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:preferably variant fc region least one amino acid substitution compared native sequence fc region fc region parent polypeptide e g one ten amino acid substitutions preferably one five amino acid substitu tions native sequence fc region fc region parent polypeptide 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody one wherein bound pcsk9 said monoclonal antibody binds least one residue within specified sequence set forth residues 123 132 seq doc id 1 wherein said monoclonal antibody reduces binding individual pcsk9 regions egfa domain ldlr signaling protein antagonizes host pcsk9 inhibition cellular cellular ldl uptake 
Original summary:123 132 10 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:adjacent isolated mouse monoclonal antibody wherein bound pcsk9 said monoclonal antibody binds least one residue within sequence set brought forth residues 123 132 seq id 4 1 wherein said monoclonal antibody reduces binding pcsk9 egfa domain part ldlr protein antagonizes pcsk9 inhibition cellular ldl uptake 
Original summary:123 132 10 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:effector functions ly thc fc region bc combined g e g assessed using assays kno vn art evalu ating antibody functions sequence tc region mi amu o amd sequence tical tlm amino acid cc ofan fc region d fc region comprises ail a s 1 acid sequence wh ch differs native sequence fc region least one nmino acid yet retains least one effector h native sequence fc rey'on 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:ivnentino aclimed is omonlconal anitobdy thta spcefiicalyl binds k2 domain kunizt domain 2 tfpi wherein said natibdoy sepicfically bidns epitope comprising residues e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:another aspect present invention provides isolated pcsk9 specific antagonists and specific embodiments antibody molecules comprise heavy and or light chain variable regions comprising amino acid sequences homologous corresponding amino acid sequences disclosed antibodies wherein anti body molecules inhibit pcsk9 dependent inhibition cel lular ldl uptake 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:certain embodiments pcsk9 epitope utilized isolate antibodies antigen binding proteins bind pcsk9 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monocloanl atniobdy binsd pcsk9 wehreni isolated monocloanl natbiody binds epitope comprising least one residues 3 4 seq id no 5 wherein monolconal antibdyo blocks binding pcsk9 ldrl 
Original summary:237 238 3 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:biotech 7 4 1996 et al 13 2 222 245 et al 113 2 211 222 et al 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal wherein hound pcsk9 monoclonal antibody binds least one following residues s153 i154 p145 r194 d238 a239 i369 s372 d373 t37i c378 f379 v380 s381 seq id no 3 wherein monoclonal ant glocks binding pcskp ldkr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:claimed is 1 isolated monoclonal antibody wherein bound pcsk9 antibody binds least one residue within set residues 123 132 seq id no 1 l antibody binding pcsk9 egfa domain ldlr antagonizes pcsk9 inhibition cellular ldl uptake 
Original summary:123 132 1 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:monoclonal binds pcsk9 wherein monoclonal antibody lbinds epi least one residues 3 4 seq id no 5 antibody ing pcsk9 ldlr 
Original summary:237 238 3 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:suitable excipients include stabilizing agents emulsifying ts salts f ir varying os encapsulating agents 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody specifically binds hpcsk9 comprising a heavy chain complementarity determining region 1 chdr1 comprising amino acid sequence least 95 identical seq id no 76 b heavy chain complementarity determining region 2 hcdr2 comprising amino acid sequence thta least 95 identical seq id no 78 c heavy chain complementarity tdeerminign region 3 hcdr3 comprsiing amino acid sequence least 95 identical seq id no 80 d light chain complementarity determining region 1 lcdr1 comprising amino acid sequence least 95 idneticla seq id no 84 e ilght chain complementarity determining region 2 lcdr2 comprising amino acid sequence taht least 95 identical seq id no 86 f light chain complementarity determining region 3 lcdr3 comprising amino acid sequence least 95 identical seq id no 88 2 antibody antigen binding fragment antibody claim 1 wherein antibody natgien binding fragment antibody binds epitope comprising amnio acid residue 238 hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:according gene fragment expression assays open reading frame encod ng pcsk9 fragmented either spec fic genetic construct ons reac thc express cd s tlm antibody tested s detennu ed 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isoaltde monoclonal antoibdy ibnds psck9 hwerien isoaletd omoncolnal antibody binds epitope pcsk9 comprising least one residues 237 238 seq id no 3 wehrien monoclonal antibody blokcs binding pcks9 ldlr 
Original summary:237 238 3 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:detailed description invention mixed monoclonal antibody k2 antigen domain kunitz domain 2 identified tfpi wherein antibody specific binding comprise residues e10 e11 d12 p13 r17 y19 t21 the epitope binding y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 residues aids seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody binds pcsk9 wherein isolated monoclonal antibody binds epitope pcsk9 compki8in9 least one kesidoes 237 238 seq i0 no 3 wherein munoc10nal anti60dy blocks 6indin9 pc8k9 ldlr 
Original summary:237 238 3 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:additionally mice result cross kirin tc mice medarex minilocus humab mice generated 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:amount percentage reduc tion similar reported pcsk9 — — mice pcsk9 knock out mice suggesting one achieve complete near complete inhibition pcsk9 function blocking extracellular pcsk9 only ellular pcsk9 little role down regulating ldlr normal physiological conditions 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:field invention 0003 present invention relates antibodies e g full length antibodies antigen binding portions thereof pep tides aptamers antagonize activity lar proprotein convertase subtilisin kexin type 9 pcsk9 including interaction low density lipoprotein ldl receptor ldlr 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:animal procedures female balb c mice 6 12 weeks old harlan uk immunised subcutaneous injection administered 0 2 ml dose volume 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:kits invention include one comprising pcsk9 antagonist antibody such human ized antibody peptide described herein instructions use accordance methods f invention described herein 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:instances antibodies include least one variable heavy chain one variable light chain listed table 2 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:since antigen processing expressed proteins occurs different pathway kinetics different acquired proteins co delivery dna associated cognate protein would provide additive synergistic effect two modes antigen presentation improved immune response 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody wheerni bound pcs9k onmolconal antibody binds least one flolownig residues s153 i154 p155 r149 d283 a239 i369 s372 d374 c375 t377 c738 f379 v380 s381 seq id no 3 wherein monoclonal antibody lbocks bindngi pcsk9 ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody competes binds pcsk9 wherein isolated monoclonal antibodies antibody binds epitope pcsk9 comprising least one residues 277 278 c seq id number 8 wherein also monoclonal antibody blocks binding pcsk9 ldlr 
Original summary:277 278 8 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:specific embodiments herein provide iso lated nucleic encoding light chain cdr seq id no 7 in specific embodiments said nucleic acid comprises seq id no 8 vki 4 place nucleic acid encoding relevant cdr 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:second cleavage event occurs pro domain catalytic domain giving rise active protease 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:used herein refers non e g im mitibodies eric immu inununoglobulin ns thereof such fv 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody wherein 6ound pcsk9 8aid monoclonal antibody binds least une residue within 8eqoence set forth 6y residues 544 882 sbq id no 90 wherein said monoclonal antibody reduces binding pgsk9 egfa domain ldlr protein antagonizes pcsk9 inhibition cellular ldl uptake 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody wherein perfectly bound pcsk9 monoclonal antibody binds least half one seven following code residues within s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 seq program id page 10 wherein modified monoclonal antibody blocks binding pcsk9 ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 10 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:active ingredient may either dissolved pre mixed emulsion composition alternatively may dissolved oil e g soybean oil oil cottonseed oil sesame oil corn oil almond oil emulsion formed upon mixing phospholipid e g egg phospholipids soybean phospholipids soybean lecithin water 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody specifically binds hpcsk9 comprising heavy chain complementarity determining region 1 hcdr1 comprising amino acid sequence least 95 identical seq id 76 b heavy chain complementarity determining region 2 hcdr2 comprising amino acid substitution sequence least 95 identical seq id 78 c heavy chain complementarity determining region 3 hcdr3 comprising abdominal amino acid sequence least 95 identical seq id 6 80 light chain complementarity determining region 1 lcdr1 comprising amino acid sequence expansion least 95 identical seq id 84 e light chain complementarity determining region 2 lcdr2 structurally comprising amino acid sequence least 95 identical seq id id 86 f light chain complementarity determining region 3 lcdr3 comprising approximately amino acid sequence least 95 identical seq id 88 2 antibody antigen binding fragment antibody claim 1 contains wherein antibody antigen binding fragment antibody binds epitope comprising amino acid residue 238 hpcsk9 seq id 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody wherein bound pcsk9 binds least one following residues i154 p155 r19 a239 i369 s372 d374 c375 c378 f379 v380 s381 seq id no 3 wherein antibody bloqks binding pcskp ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody specifically binds hpcsk9 comprising a heavy chain complementarity determining region 1 hcdr1 comprising amino acid sequence least 95 identical seq id no 76 b heavy chain complementarity determining region 2 hcdr2 comprising amino acid sequence least 95 identical seq id no 78 c heavy chain complementarity determining region 3 hcdr3 comprising amino acid sequence least 95 identical 8eq id no 80 d light chain complementarity determining region 1 lcdr1 comprising amino acid sequence 1east 95 identical seq id no 84 e light chain complementarity determining region 2 lcdr2 comprising amino acid sequence least 95 identical t0 seq id no 86 f light chain complementarity determining region 3 lcdr3 c0mpkisin9 amino acid sequence least 95 identical t0 seq id no 88 2 antibody antigen binding fragment antibody claim 1 wherein antibody antigen binding fragment antibody binds epitope comprising amino acid residue 238 hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody whekein bound pcsk9 said m0nuc1onal antibody binds least one residue within sequence set forth residues 544 582 uf seq id no 90 wherein said monoclonal anti6udy reduces binding 6etween pc8k9 egfa dumain ldlr protein antagonizes pcsk9 inhibition cellular ldl uptare 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:screen ng us ng b score surface plasmon described tlm examples lmrein binding may bc using kinexa sor muy essays 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:transgenic animals designed pro duce desirable robust immune response may also used generation humanized human antibod ies 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:moreover one skilled art generate test variants containing single amino acid substitution desired amino acid residue 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:one embodiment pcsk9 antagonist antibody peptide aptamer administered via site specific tar local delivery techniques 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:embodiments pcsk9 antagonist antibody peptide aptamer phar maceutically acceptable excipient may various formu lations 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:agents include limited to vitro prepared chemical compositions antibodies antigen binding regions combinations thereof 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:understood compositions comprise one pcsk9 antagonist antibody e g mixture pcsk9 antagonist antibodies recognize different epitopes pcsk9 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:pcsk9 proteins purified nickel affinity chromatography ion exchange chromatography size exclusion chromatography 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:are i determining nucleotide predicted amino acid sequence starting antibody light heavy variable domains 2 designing human ized antibody i e deciding antibody framework region use humanizing process 3 actual humanizing methodologies techniques 4 tion expression humanized antibody 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody bines pcsk9 man binds epitope beast one residues 3 4 seq id no 5 wherein antibody blocks rcsk9 ldlr 
Original summary:237 238 3 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody binds pcs9k whreein isolaedt monoclonal natiobdy ibnds petiope cmorpisnig laest one residues 3 4 seq id no 5 hwereni monoclonal antibody blocks bindngi pcsk9 ldlr 
Original summary:237 238 3 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:core residues 31a4 antibody follows heavy chain f29 a31 y32 y33 r56 k76 g98 light chain s31 d94 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:0016 still another embodiment invention provides antibody specifically binds pcsk9 comprising vh complementary determining region one cdri amino acid sequence shown seq id no 8 vh cdr2 amino acid sequence shown seq id no 9 and or vh cdr3 hav ing amino acid sequence shown seq id no 10 variant thereof one conserva tive amino acid substitutions said sequences cdri cdr2 and or cdr3 wherein variant retains essentially binding specificity cdr defined said sequences 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:embodiments vh least 90 sequence identity amino acid sequence selected group consisting seq id no 74 85 71 72 67 87 58 52 51 53 48 54 55 56 49 57 50 91 64 62 89 65 79 80 76 77 78 83 69 81 60 and or vl least 90 sequence identity amino acid sequence selected group consisting seq id no 5 7 9 10 12 13 15 16 17 18 19 20 21 22 23 24 26 28 30 31 32 33 35 36 37 38 39 40 42 44 46 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody specifically binds hpcsk9 comprising a heavy chain complementarity determining region 1 hcdr1 comprising amino acid sequence least 95 identical seq id no 76 b heavy chain complementarity 2 hcdr2 comprising amino acid sequence least 95 identical seq id no 78 c heavy chain complementarity determining region 3 hcdr3 comprising amino acid least 95 identical seq id no 80 d light chain complementarity determining region 1 lcdr1 comprising amino acid sequence least 95 identical seq id no 84 e light chain complementarity determining region 2 lcdr2 comprising amino acid least 95 identical seq id no 86 f light complementarity determining region 3 comprising amino acid sequence 95 identical seq id no 88 2 antibody antigen b fragment antibody claim 1 wherein antibody antigen binding antibody binds epitope comprising a mino acid residue 238 hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody wherein bound rat pcsk9 said monoclonal antibody specifically binds least one residue within identity sequence set forth residues 544 582 drug seq id 90 therefore wherein said monoclonal antibody reduces binding human pcsk9 egfa subunit domain ldlr protein antagonizes within pcsk9 inhibition cellular ldl ion uptake 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:solvent exposure ratio residue calculated surface area residue context protein divided surface area residue flanking conserved backbone structure 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:vesicle liposomal liposome forming components used form liposomes may include neutral zwitterionic and or cationic lipid moieties 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody in bound pcsk9 siid monoclonal antibody binds one residue sequence set forth residues 544 582 seq id no 90 n said monoclonal antibody binding domain ldlr protein antagonizes pcsu9 inhibition cellular ldl 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody thta specifically binds hpcsk9 comprising a heavy chain complementarity determining region 1 hcdr1 comprising amino acid sequence least 95 identical seq id no 76 b heavy hcain complementarity determining region 2 hcdr2 comprising amino acid sequence least 95 identical seq id no 78 c heavy chain complementarity deetmirning region 3 hcdr3 comprising amino acid sequence least 95 identical seq id no 80 d lihgt chian comlpmenetariyt determining region 1 lcdr1 ocprmising amino acid sequence leats 95 identical seq id no 84 e light chain complementarity determining region 2 lcdr2 comprising amino acid esqunece least 95 identical seq id no 86 f light chain complementarity determining region 3 lcdr3 comprising amino acid sequence least 95 identical seq id no 88 2 antibody antigen binding fragment antibody claim 1 wherein antibody antigen binding fragment antibody binds epitope comprising amino caid residue 238 hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:0146 viral based vectors delivery desired poly nucleotide expression desired cell well known art 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:overnight incubation 4° c wells washed four times pbs tween 20™ pbst wells coated 200 μl 2 w v bsa pbs 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:purposes epitope sequences epitope based involving changes binding sequences provided reference seq id no 1 and or seq id no 303 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:invention claimed i8 monoclonal antibody specifically binds k2 domain kunit2 domain 2 tfpi wherein said antibody specifically binds epitupe comprising residues e10 e11 d12 p13 r17 y19 t21 yz3 n26 q28 q31 c32 b33 r34 k3b l50 8eq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:rna molecules uiclude molecules contain introns correspond dna molecule one to one manner md mrna molecules wluch introns 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:354 1264 1272 wherein humans heterozygous mutated loss function pcsk9 exhibited significant reduction long term risk developing atherosclerotic heart disease 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibdyo whreien wehn boudn pcsk9 monoclonal antibody ibnds least one flolowign residues s153 i154 p155 r914 d238 a239 i369 s372 d374 c375 t377 c378 f739 v380 s381 seq id no 3 wherein monoclonal antibody blocks binding psck9 ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:monoclonal antibody wherein boun pc k9 said monoclonal antibody binds least one residue wi hin set forth residues 544 582 seq id no 90 wherein said monoclonal antibody reduces binding pcmk9 egfa domait ldlr antagonizes pcsk9 cellular ldl uptake 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody hweerin bound cpsk9 monoclonal antibody binds least one following residues s135 i154 p515 r194 2d38 a239 i369 s372 d374 c375 t377 c378 f397 v308 s381 seq id no 3 wherein monoclonal antibody blcoks binidgn pcsk9 dllr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:t cells recognize peptide fragments proteins embedded class ii class i mhc antigens surface cells whereas b cells which ultimately produce antibody recognize surface features antigen which usually protein character via antibody like antigen receptors cell 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment individual antibody specifically binds hpcsk9 comprising heavy chain complementarity determining region 1 hcdr1 comprising amino acid sequence least 95 identical seq id ii 76 b heavy chain complementarity determining region 2 hcdr2 comprising amino acid sequence least 95 identical seq id 78 c heavy chain complementarity determining region 3 hcdr3 comprising amino acid sequence least 95 identical seq id 80 light chain complementarity determining region 1 lcdr1 comprising amino acid sequence essentially least 95 identical back seq id 84 e third light chain complementarity determining region 2 lcdr2 comprising amino acid sequence least 95 identical seq id 86 f light chain complementarity determining region 3 lcdr3 comprising amino acid sequence least within 95 identical seq id 88 2 antibody antigen binding fragment antibody extension claim 1 wherein antibody antigen binding fragment antibody binds epitope comprising amino acid residue 238 hpcsk9 seq id 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:specific binding antibody diagnosis antigen substrate binding fragment hpcsk9 specifically binds hpcsk9 including a heavy chain complementary determination region 1 hcdr1 comprising amino acid sequence least 95 seq id no 76 b heavy chain complementary determination region 2 hcdr2 comprising amino acid sequence 95 identical seq id no 78 c contains heavy chain complementary determination regions 3 hcdr3 including amino acidssequence exactly amino acid sequence seq id no 80 d light chain complementary determination region 1 lcdr1 comprising amino acid sequence least 95 seq id no 84 e light chain complementary determination region 2 lcdr2 comprises amino acid sequenceit least 95 seq id no 86 f light chain complementary determination region 3 lcdr3 comprising amino acid sequences seq id no 88 2 claim 1the antibody antibody antigen binding fragment wherein antibody antigen binding fragment antibody binds epitope amino acid residue 238 comprising hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:addition clear neutralizing abps 21b12 31h4 resulted greater increase ldlr levels even presence statins 25a7 1 abp a non demonstrating additional benefits achieved use statins abps pcsk9 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:recombinant humanized antibodies fc portion modilied avoid interaction fc receptor aud complement systems 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:following 1 h incubation 37° c plates washed four times pbst overlaid 50 μl well rabbit anti mouse ig hrp conjugated sera dako 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated munoc1unal antibody binds t0 pcsk9 wherein isolated monoclonal antibody binds epitope pcsk9 compki8in9 lea8t 0ne 0f residues 237 0r 238 seq id no 3 wherein monoclonal antibody blocks binding pcsk9 l0lr 
Original summary:237 238 3 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:invention presently claimed candidate monoclonal antibody specifically binds k2 domain kunitz domain 2 protein tfpi wherein said antibody also specifically specifically binds epitope comprising residues e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 possibly q31 otherwise c32 e33 r34 k36 l50 seq id 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody ibnds psck9 weherin iosalted monoclonal antibody binds epitope comprising least one residesu 3 4 seq id no 5 hwereni moonclnoal naitbody lbocks binding pcsk9 ldlr 
Original summary:237 238 3 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monocloanl antibody binds pcs9k wherein isolated monoclonal atniobdy binsd epitope ocmpriisgn lesat one residues 3 4 seq id no 5 wherein mnooconlal antibody lbocks binding pcs9k lldr 
Original summary:237 238 3 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:embodiments first manner comprises first ec50 wherein second manner involves second ec50 wherein point mutation selected group consisting comprising r207e d208r e181r r185e r439e e513r v538r e539r t132r s351r a390r a413r e582r 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:incubate overnight 4° c overnight incubation wells washed four times pbs tween 20™ pbst wells coated 200 μl 2 w v bsa pbs 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody wher ei n bound pcsk9 1said monoclonal bin ds one residue within sequence set forth residues 544 582 seq id no 90 monoclonal antibody reduces binding pcsk9 egfa domain ldlr antagonizes inhibition cellular ldl 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:prior pre freeze dry process sucrose added vial lipid sucrose ratio w w 1 3 allowed rt brahim z gregoriadis g novel method high yield entrapment small liposomes j liposome research 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:invention claimed monoclonal antibody compound specifically binds k2 domain kunitz domain type 2 ec tfpi e wherein said antibody specifically binds epitope comprising 10 residues e10 e11 d12 p13 r17 y19 t21 y23 ec f24 n26 q28 q31 c32 bp e33 r34 k36 l50 seq id 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody binds pcsk9 isolated monoclonal antibody bidds epi least one re 3 4 seq id no 5 l bkocks binding posk9 ldlr 
Original summary:237 238 3 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:invention cilamed is monoclonal antibody specifically binds k2 domian kuntiz domain 2 tfip wheerni sadi atnibdoy specifically bidns epitope comprsiing residues e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:et al athemsclerosis ct al 2006 hummi molecular 15 i am et al logy metabolism 17 79 31 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:monoclonal binds pcsk9 wherein monoclonal antibody binds epitope q least one 237 238 seq id no 3 wherein monoclonal antibody bin pnsk9 l lr 
Original summary:237 238 3 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:resulting collected media sample hybridoma line spun remove cells debris 15 minutes 3000 rpm resulting supernatant filtered 0 22 um 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:e g full antibodies binding portions thereof pcptides aptamers activity convertase subtilisin kexin type 9 including die lou density lipoprotein i di 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:example direct reac tion agent antibody possible possesses capable reacting other 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody binds pcsk9 wherein thus isolated monoclonal antibody binds epitope receptor pcsk9 comprising upon least one residue either residues 277 278 seq id 8 wherein monoclonal antibody blocks binding pcsk9 influenza ldlr 
Original summary:277 278 8 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:example c s id no 24 3 5 nm bet can carboxy terminus onc variable region amino ter m due variable region 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated antibody wherein bound pcsk9 monoclonal antibody binds least one following resisuss s 53 i154 p155 d238 i369 d374 c 75 t377 c378 f379 v380 s381 seq id no 3 wherein antibody blocks 9csk9 ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:pcsk9 zymogen occurs naureckiene et al 2003 shown required secretion cells seidah et al 2003 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:structures a xl tluee dimensional ons classes well known 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody specifically binds hpcsk9 comprising heavy chain complementarity determining region 1 hcdr1 instead comprising amino acid sequence least 95 identical seq id 76 b heavy chain complementarity determining region 2 hcdr2 comprising amino acid sequence least 95 identical seq id 48 78 c heavy chain complementarity determining region 3 hcdr3 comprising amino acid sequence least 95 identical seq id 80 light chain antibody complementarity determining region 1 lcdr1 comprising amino acid sequence least approximately 95 identical seq id 84 e light chain complementarity determining region 2 lcdr2 comprising amino acid sequence least 95 identical seq id 86 f light chain complementarity determining region 3 lcdr3 comprising encoded amino acid sequence least 95 identical seq id ed 88 2 alternatively antibody antigen binding fragment antibody claim 1 wherein antibody antigen binding fragment antibody binds epitope comprising amino acid residue 238 hpcsk9 seq id 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:typically experimental isolated monoclonal antibody binds pcsk9 wherein typically isolated monoclonal envelope antibody binds epitope pcsk9 alone comprising typically least one seven residues 277 position 278 seq id 8 wherein monoclonal enveloped antibody blocks binding factor pcsk9 ldlr 
Original summary:277 278 8 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antbioyd wherein bound pcks9 said monoclonal atniboyd binds least one residue within sequence set forth reisduse 544 582 seq id no 90 hwreein asid monooclanl antibody reduces binding cpsk9 egfa domain ldlr protein naatgoniezs pcks9 inhibition cellular ldl uptake 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:binds pcsk9 wherein m binds comprising leaast one residues 3 4 seq id no 5 wherein monoclonal blocks binding pcsk9 lsdlr 
Original summary:237 238 3 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:moreover guidelines suggest even ldi levels achieved order hi h risk patients c na mi tional 1 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:provides great flexibility adjusting mutual proportions three polypeptide fragments embodiments unequal ratios three polypeptide chains used construction provide yields 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody wherein bound exclusively pcsk9 monoclonal antibody protein binds least one following residues unidentified s153 including i154 containing p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 mali seq id residue 10 wherein monoclonal antibody blocks binding pcsk9 ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 10 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:followed claimed 1 isolated group monoclonal antibody wherein directly bound pcsk9 said monoclonal antibody binds least one residue already within sequence set forth residues 123 132 sequence seq id 1 wherein said individual monoclonal antibody specifically reduces binding specific pcsk9 egfa domain ldlr protein antagonizes pcsk9 inhibition important cellular ldl uptake 
Original summary:123 132 1 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:following 1 h incubation 37° c plates washed four times pbs tween 20 overlaid dilutions murine specific influenza a sichuan dilution 1 5000 50 μl sample well 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:50 c 30 for2min 52 30 sec 72 c 2 min follo 35 cycles 9 4 c fbr 30 sec 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:claimed is monoclonal antibody phat speci binds k2 domain dom7in 2 tfpi specifically epitope comprising e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:naked dna vectors gene therapy introduced desired host cells methods known art e g electroporation microinjection cell fusion deae dextran calcium phosphate precipitation use gene gun use dna vector see e g et al j biol 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:background invention 0004 people u s risk heart disease resulting events 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:claimed is monoclonal bfinds k2 domain kunitz domain 2 tifpi wherein saiod binds comprising es e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:monoclonal binds pcsk9 wherein isolated antibody bindz pcsk9 comprising leawt one residues 237 238 seq id no 3 wherein na antibody blocks b pcsk8 lwlr 
Original summary:237 238 3 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:claimed is 1 isolated antibody wherein bound pcsk9 said monoclonal binds least one residue within set forth residues 123 132 seq id no 1 wherein said antibody reduces binding pcsk9 egfn domain ldlr protein inhibition ldl uptake 
Original summary:123 132 1 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:claimed is 1 monoclonal antibody wherein bound pcsk9 said monoclonal binds least one residue sequence set forth 123 132 seq id no 1 in said monoclonal reduces binding pcsk9 dpmain ldlr protein antagonizes pcsk9 c ldl uptake 
Original summary:123 132 1 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:ahtifody antigen fragment antibody specifically binds hpcsk9 comprising a chain complementarity determining region 1 hcdr1 comprising amino acid sequence least 95 identical seq id no 76 b heavy chain complementarity determining region 2 hcdr2 comprising amino acid sequence least 95 identical seq id no 78 c heavy chain complementarity determining region 3 hcdr3 comprising amino acod sequence least 95 identical seq id no 80 d light chain complementarity region 1 lcdr1 comprising amino acid sequence least 95 id seq id no 84 e light chain complementarity determining region 2 lcdr2 comprising amino acid sequence least 95 identical seq id no 86 f light chain determining region 3 comprising amino acid sequence least 95 identical seq id no 88 2 antibody antigen binding antibody claim 1 wherein antibody antigen binding fragment antibody binds epitope comprising amino acid residue 238 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:claimed is monoclonal antibody thzt specifically binrs k2 domain kunitz domain 2 tfpi sa d antibody bonds xomp e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated large monoclonal antibody normally binds pcsk9 wherein isolated small monoclonal antibody binds epitope expressed pcsk9 comprising least one residues 237 residue 238 seq id part 3 wherein alternatively monoclonal antibody blocks binding groups pcsk9 ldlr 
Original summary:237 238 3 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:u lar pcs k 9 p little role ui down regulating ldlr normal physiological conditions 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:ivnentino caliemd is monoclonal antibody specifically ibnds k2 dmoain knuitz domani 2 tfip wherine said antibody spcefiiaclly binds epitope comprising resdieus e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody specifically binds hpcsk9 comprising a heavy chain complementarity determining region 1 hcdr1 comprising amino acid sequence least 95 identical seq id no 76 b heavy chain complementarity determining region 2 hcdr2 comprising amino acid sequence least 95 identical seq id no 78 c heavy chain complementarity detekminin9 region 3 hcdr3 comprising amino acid sequence least 95 identica1 seq id no 88 d light chain complementarity detekminin9 region 1 lcdr1 comprising amino acid sequence least 95 identical seq id no 84 e light chain complementarity detekminin9 region 2 lcdr2 comprising amino acid sequence least 95 identical seq id no 86 f light chain complementarity determining region 3 lcdr3 comprising amin0 acid sequence 1east 95 identical seq id no 88 2 antibody antigen binding fragment antibody claim 1 wherein antibody antigen binding fragment antibody binds epitope comprising amino acid residue 238 hpgsk9 seq 1d no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody claim 2 wherein antibody recog nizes epitope human pcsk9 overlaps 75 surface pcsk9 interacts egf like domain ldlr 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:currently claimed example 1 tested isolated monoclonal antibody tested wherein specifically bound pcsk9 said monoclonal antibody binds least one residue within sequence set forth residues 123 132 type seq id 1 wherein said monoclonal antibody specifically reduces binding pcsk9 egfa domain fixed ldlr protein antagonizes pcsk9 inhibition cellular ldl uptake 
Original summary:123 132 1 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:monoclonal antibody separated therein wherein small monoclonal antibody bonded least one identification residue sequence listed residue connection pcsk9 binds 132 seq site id no 1 and wherein monoclonal antibody portion reduces binding adjacent pcsk9 uses ldlr protein antagonize inhibition pcsk9 cell ldl intake 
Original summary:123 132 10 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated rat monoclonal antibody wherein bound pcsk9 monoclonal antibody binds least one 4 following residues s153 containing i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 seq id 10 wherein mouse monoclonal candidate antibody blocks binding pcsk9 ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 10 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:reaction stopped adding 50 μl well stopping solution 2m sulphuric acid absorbance well 450 nm determined 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:apparent person skilled tint examples herein intended limiting illustrative ac 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody biuds isolated monoclonal bifds comprising least one 3 4 seq id no 5 wherein monoclonal pcsk9 ldlr 
Original summary:237 238 3 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:surface area residues i er buried surface area fcsk9 antibody complex i dlr pc'sk9 con plex values ldlr pcsk9 complex 100 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:'k invfntion people tile u s risk heart disease tmd resulting events jv underlying atheroscle rosis cause among groups despite availability directed multiple risk atherosclerosis disease ies responsible coronary heart disease associated 4 many deaths industrialized countries 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody responses sera elisa expressed mean n 5 animals group od signal±sem log 10 serum dilution assayed 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:hybridoma cell lines screened selected identify hybridoma cell lines produced antibodies specific antigen interest 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:levels measured tlmt day 2 fici 18 illustmtes thc eifect ol'nti pc'sk9 antibody 7d4 nn plasma levels cynomolgus monkeys fed 33 4 dict en w th 0 1 cholesterol 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:aspects invention comprises method treating preventing condition associated elevated serum cholesterol levels patient comprising administering patient need thereof effective amount least one isolated antigen binding protein disclosed herein 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:different modifications constant region may used achieve optimal level and or combination effector functions 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal natbiody bidns pcsk9 wehrien isolated monoclonal antibody binds epiteop pcsk9 comprising lesat one residues 237 238 seq id no 3 wehrien monoclonal antiobyd blocks binding pcs9k dllr 
Original summary:237 238 3 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:immune response requires co different cells immune system namely antigen presenting cells such macrophages dendritic cells known antigen presenting cells t cells t lymphocytes b cells b lymphocytes 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:is 1 isolated monoclonal antibody wherein bound pcsk9 said monoclonal antibody binds least one residue sequence set forth esiduss 123 132 seq id no 1 xaid monoclonal antibody reduces binding pcek9 egfw d main ldlr protein pcsko inhibition cellular ldl uptake 
Original summary:123 132 1 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:membrane separating two chambers permeable small molecular weight nutrients impermeable hybridoma cells antibodies produced cells 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody whekein bound tu pcsk9 monoclonal antibody binds least one following residues s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 v380 s381 seq id no 3 wherein monoclonal antibody blocks binding pcsk9 lolr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:monoclonal antibody incompletely separation wherein particular combined pcsk9 monoclonal antibody may combined least one five residues s153 i154 p155 r194 may d238 a239i369 s372 may d374 possibly d374c375 t377 perhaps c378 f379 possible seq id no 10 v380 s381 wherein monoclonal antibody blocks subsequent bonding pcsk9 ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 10 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody specifically binds hpcsk9 comprising heavy chain complementarity determining region 1 hcdr1 comprising amino acid sequence least 95 identical relative seq id 76 b heavy chain complementarity determining region 2 hcdr2 comprising amino acid sequence least 95 identical seq id 78 c heavy chain restriction complementarity determining determining region 3 hcdr3 comprising amino acid sequence least 95 identical seq id 80 light chain complementarity determining region 1 lcdr1 comprising amino acid sequence consisting least 95 identical seq id 84 e light chain complementarity determining region 2 lcdr2 comprising amino acid tag sequence least 95 identical seq id 86 f light chain complementarity determining region 3 lcdr3 comprising amino acid sequence least 95 identical seq id 88 2 within antibody antigen binding fragment designated antibody claim 1 wherein antibody antigen binding tagged fragment antibody binds epitope comprising amino acid coding residue 238 hpcsk9 seq id 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:words antigen binding protein block pcsk9 binding ldlr prevent reduce pcsk9 mediated ldlr degradation 
Original summary:no data 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:also included within definition are example polypeptides containing one analogs amino acid including example unnatural amino acids etc 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody specifically binds hpcsk9 comprising containing heavy chain complementarity determining region 1 hcdr1 comprising amino acid sequence least 95 identical seq id 76 b heavy chain complementarity determining region 2 hcdr2 comprising amino acid sequence probably least 95 identical hiv seq id 78 c heavy chain complementarity determining region 3 hcdr3 comprising individual amino acid sequence likely least 95 identical seq id 80 light chain complementarity determining region 1 lcdr1 comprising amino acid sequence least 95 identical seq id 84 e light chain complementarity determining region 2 lcdr2 comprising amino acid sequence least 95 identical seq id 86 f light chain complementarity determining regional region 3 lcdr3 comprising amino acid sequence least 95 identical seq id 88 plot 2 antibody antigen binding protein fragment antibody claim 1 wherein antibody antigen binding fragment antibody binds epitope comprising amino acid residue type 238 hpcsk9 seq id 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated conditional monoclonal antibody including wherein perhaps bound briefly pcsk9 monoclonal antibody binds always least one following residues s153 i154 p155 r194 d238 a239 i369 s372 d374 oh c375 t377 c378 f379 v380 s381 et seq id 10 wherein monoclonal antibody blocks binding pcsk9 ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 10 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:certain embodiments variety expression vector host systems utilized express polynucleotide molecules encoding polypeptides comprising one abp components abp itself 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody pcsk9 wherein separated human monoclonal antibody binds envelope epitope pcsk9 incluspect comprising least one residue 277 chip seq id no 2 8and usually wherein monoclonal antibody prevents binding pcsk9 ldlr 
Original summary:277 278 8 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:claimed is 1 isoaletd monoclonal antibody hwereni bound pcsk9 sadi monoclonal antibody binds leats one residue within seuqenec set forth residues 123 132 seq id no 1 wherein said monoclonal antibody reduces bnidign pcs9k egfa domain ldlr protein antagonizes cpsk9 inhibition cellular ldl uptkae 
Original summary:123 132 1 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:background various embodiments proprotein convertase subtilisin kexin type 9 pcsk9 serine protease involved regulating levels low density lipoprotein receptor ldlr protein horton et al 2007 seidah prat 2007 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment natbiody sepcificayll binds hpcsk9 comprising a heavy chain complementarity determining region 1 hcdr1 comprising amino acid sequence least 95 identical seq id no 76 b heavy chain complementarity determining region 2 hdcr2 comprising amino acid sequence least 95 identical seq id no 78 c heavy chain complmeenatiryt determining ergion 3 hcdr3 comprising amino acid sequence least 95 identical seq id no 80 d light chain complementarity determining region 1 lcdr1 comprising amino acid sequence least 95 identical seq id no 84 e light cahin complementarity determining region 2 lcdr2 comprising amino acid sequence least 95 identical seq id no 86 f light chain complementarity determining region 3 lcdr3 comprising maino acid sequence least 95 identical seq id no 88 2 antibody antigen binding fragment antibody claim 1 wherein antibody antigen binding fragment antibody bnids epitope comprising maino acid residue 238 phcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:certain embodiments within included certain embodiments within 5 included 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:0106 present invention encompasses nucleic acid encoding antibody molecules comprise i nucleic acid encoding light chain comprising seq id no spe cific embodiments comprise nucleic acid seq id no 2 ii nucleic acid encoding heavy chain compris ing seq id no 11 specific embodiments com prise nucleic acid seq id no 12 followed sequence adjacent to set nucleotides encoding set amino acids selected group consisting of seq id no 21 iggi seq id no 22 igg2 seq id no 23 igg4 seq id no 24 igg2 m4 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:therefore improvement present invention exemplified experiment ability induce clear antibody response several different antigenic strains following single immunization formulation containing dna protein antigens strains 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:cdrs two chains pair typically aligned framework regions enable binding specific epitope 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibodies antibody wherein bound pcsk9 said monoclonal antibody binds repeat least one residue within dna sequence set forth residues 544 page 582 seq id specimen 90 wherein said monoclonal antibody reduces binding links pcsk9 protein thus egfa domain ldlr protein antagonizes pcsk9 inhibition cellular ldl uptake 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:ated monoclonal antibody binds pcsk9 isolated mon antibody bknds comprising l4ast one residues 3 4 seq id no 5 monoclonal antibody blocks pcsk9 ldlf 
Original summary:237 238 3 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody wherein bound tu pcsk9 said m0n0clona1 antibody binds least one residue within sequence set forth residues 544 582 seq id nu 90 wherein said monoclonal antibody reduces 6indin9 pcsk9 egfa dumain ldlr pkutein anta9oni2e8 pcsk9 inhibition uf cellular ldl uptake 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody yinds pcsz9 isolated monoclonal antibody bin s epitope least one residues 3 4 seq id no 5 l antibody blocks pcsk9 ldlr 
Original summary:237 238 3 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:wyat claimed is 1 isolated wher n bound pcsk9 said monoclonal antibody binds least one residue sequence set residues 123 132 seq id no 1 wherein zaid monoclonal antibody reduces binding pcsko egfa domain ldlr protein pcsk9 inhibition cellular ldl uptake 
Original summary:123 132 1 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:siolatde mooncloaln antibody ibnds cpsk9 wherein isolated monoclonal natiobdy binds epitope pcsk9 comprising least one residues 237 238 seq id no 3 wherein monoclonal naitbody blocsk binding cpsk9 ldrl 
Original summary:237 238 3 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:hybrid antibod ies prepared binding spec i'a pcsk9 monoclonal antibody herein 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:protocol employed screen 384 member blocker subset assay done large scale receptor ligand blocking screen 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:unlike prime boost nucleic acid vaccine field novel compositions provide prime boost functions single dose 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:is monoclonal antibody bohnd pcsl9 monoclonal antibody binds lesst one following residues s153 i154 r194 d238 i369 s3 2 d374 c375 t377 c378 f379 v 80 s381 seq id no 3 wherein monoclonal antibody blocks pcsk9 ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody specifically binds hpcsk9 comprising a heavy chain complementarity determining region 1 hcdr1 comprising amino acid sequence 1east 95 identical seq id no 76 b heavy chain complementarity determining region 2 hcdr2 compki8in9 amino acid sequence least 95 identical seq id no 78 c heavy chain complementarity determining region 3 hcdr3 comprising amino acid sequence least 95 identical seq id no 80 d light chain complementarity determining region 1 lcdr1 comprising amino acid sequence least 95 identical seq id no 84 e light chain complementarity determining region 2 lcdr2 comprising amino acid sequence least 95 identical seq id no 86 f light chain complementarity determining region 3 lcdr3 comprising amino acid sequence 1east 95 identical t0 seq id no 88 2 anti60dy antigen binding fragment antibody claim 1 wherein antibody antigen binding fragment antibody binds epitope comprising amino acid residue 238 hpcsk9 seq id nd 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:certain embodiments techniques ” ” used produce humanized antibodies 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:modified polypeptides made using established procedures art screened using standard assays known art described examples 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:example 19 uses pcsk9 antibodies treatment cholesterol related disorders human patient exhibiting cholesterol related disorder in reduction cholesterol such serum cholesterol beneficial administered therapeutically effective amount pcsk9 antibody 31h4 or example 21b12 16f12 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:pcsk9 blocking murine antibod ies 4a5 7d4 5aio 6f6 expressed transient transfection cells purified protein g column eluted 0 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody specifically binds hpcsk9 comprising a heavy chain complementarity determining region 1 hcdr1 comprising amino acid sequence least 95 identical seq id no 76 b heavy chain complementarity determining region 2 hcdr2 comprising amino acid sequence 1east 95 identical seq id no 78 c heavy chain complementarity determining region 3 hcdr3 comprising amino acid sequence least 95 identical tu seq id no 80 d light chain determining region 1 lcdr1 comprising amin0 acid sequence least 95 identical seq id no 84 e light chain complementarity determining region 2 lcdr2 comprising amino acid sequence least 95 identical seq id no 86 f light chain complementarity determining region 3 lcdr3 comprising amino acid sequence least 95 identical seq id no 88 2 antibody antigen 6indin9 fragment antibody 0f claim 1 wherein antibody antigen binding fragment antibody binds epitupe comprising amino acid residue 238 hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:certain embodiments polypeptide comprising one abp components abp expressed insect system 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal binds pcesk9 wherein antibody binds comprising least one residues 3 4 seq id no 5 wherein binding pcfsk9 l dlr 
Original summary:237 238 3 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monuc10nal antibody binds pcskg wherein isolated monoclonal antibody binds epitope pcsk9 comprising lea8t one 0f residues z37 238 uf seq id no 3 whekein monoclonal antibody blocks 6indin9 pcsk9 ldlr 
Original summary:237 238 3 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated multiple monoclonal antibody binds targets pcsk9 wherein isolated monoclonal antibody binds intact epitope pcsk9 comprising actually least one residues 277 278 seq id id 8 wherein monoclonal antibody completely blocks binding activity target pcsk9 ldlr 
Original summary:277 278 8 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:clear 96 well plates nunc coated overnight 2 ug ml various anti pcsk9 antibodies diluted pbs 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antiobyd wherein bound pcs9k said mnocoloanl antibody binds least one residue within sequence set forth residues 544 582 seq id no 90 hwerien said monoclonal anitboyd reduces ibndnig betewen pcsk9 egfa domain dllr protein atnagoneizs pcsk9 inhibition cellular ldl uptake 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment hpcsk9 specifically binds including a heavy chain complementary determination region 1 hcdr1 comprising amino acid sequence least 95 seq id no 76 b heavy chain complementary determinationregion 2 hcdr2 contains amino acid sequence least 95 seq id no 78 c heavy chain complementary determination region 3 hcdr3 contains least 95 seq id no 80the amino acid sequence d light chain complementary determination region 1 lcdr1 region 1 lcdr1 comprises amino acid sequence least 95 seq id no 84 e light chain complementarydetermination region 2 lcdr2 contains amino acid sequence least 95 seq id no 86 f light chain complementary determination region 3 especially lcdr3 including seq abd id no 88the amino amino amino acid sequence 2 2 antibody antigen binding fragment antibody according claim 1 wherein antibody antigen binding fragment antibody binds epitope amino amino acid residue 238 comprising hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:nucleic acid aptamers include modified bases functional groups including limited 2' nucleotides 2' 0 methyl nucle otides 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:invention claimed monoclonal antibody specifically directly binds target k2 antibody domain central kunitz virus domain 2 tfpi wherein said antibody residue specifically binds epitope comprising residues e10 e11 d12 p13 r17 y19 t21 y23 f24 sequences n26 sequences q28 q31 c32 e33 r34 k36 l50 matrix seq id e 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated nal bi ds wherein monoclonal antibody binds epitope comprising lyast one residues 3 4 seq id no 5 wherein monoclonal pcsk9 
Original summary:237 238 3 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:ivnnetion claimed is monoclnoal natiobdy htat sepicfcially binsd k2 dmoain kunitz domain 2 tfpi wherein asid antibody specifically binsd epitope comprising residues e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:certain embodiments optimal pharmaceutical composition determined one skilled art depending upon example intended route administration delivery format desired dosage 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:claimed is specifically binds k2 domain dkmain 2 tfpl wherein said antibody specifically bindx ges dues e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:100 nm 50 nm 10 21 us 8 080 243 b2 22 nm 500 pm 100 pm 60 pm 50 pm 20 pm 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody specifically binds hpcsk9 comprising a heavy chain complementarity determining region 1 hcdr1 comprising amino acid sequence rhat least 95 identical seq id no 76 b heavy chain complementarity determining region 2 hcdr2 comprising amino acid sequence least 95 identical seq id no 78 c heavy chain complementarity determining region 3 comprising amino acid sequence least 95 identical seq id no 80 d light chain complementarity determining region 1 lcdr1 comprising amino acid sequence tgat least 95 identical seq id no 84 e light chain complementarity region 2 lcdr2 comprising amino acid sequence least 95 identical seq id no 86 f light chain complementarity determining region 3 lcdr3 amino acid sequence least 95 identical seq id no 88 2 antibody antigen binding antibody claim 1 antibody antigen fragment antibody binds epitope comprising qmino avid residue 238 hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody th at bbinds p csk9 isolated ibody biqnds epitope comprising one residues 3 4 seq id no 5 monoclonal antibody blocks binding pcs k9 ldlr 
Original summary:237 238 3 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal wherein bound pcsk9 monoclonal antibody binds least one following residues s154 i154 r194 a229 l369 s372 d374 c375 c378 f379 v380 s381 seq id no 3 whwreim monoclonal blocks binding pcsk9 ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:us 8 080 243 b2 is 24 a i made drs antibody 5a10 thc course affinity maturation opti particular properties 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:determination pcsk9 variant protein concentration subjects steps outlined performed using antibodies noted herein bind wild type pcsk9 variant pcsk9 d374y 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:however also possible pcsk9 could interact ldlr two proteins translated within endoplasmic reticulum er traffic endosomal compartments towards cell mem 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:consider isolated human monoclonal antibody monoclonal antibody finally binds following residues combination pcsk9 s153 i154 p155 r194 d238 a239 c375seq sequence id nothe t377 c378 f379 v380 s381 ii 10 wherein monoclonal antibody blocked binding pcsk9 expression ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 10 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:synthetic peptide based assays descnbed example n 11 on i using antibodies i manual cold pres 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:process combinatorial alanine scanning strategy used identify amino acids pcsk9 protein necessary interaction anti pcsk9 abps 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated wherein bound pcsk9 said monoclonal antibody binds least one residue sequence set forth ry idues 544 582 seq id no 90 saud monoclonal binding pcsp9 egfa domain protein antagonizes pcsk9 inhibition cellular ldl uptake 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:certain embodiments compositions selected inhalation delivery orally 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:certain embodiments capsule designed release active portion formulation point pre systemic degradation 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:sioalted monoclonal antibody binds pcks9 wherein isolated mnocloonal anitboyd binsd epitope compriisng least one residues 3 4 seq id no 5 wherein mnooclnaol atniboyd blocks binding pcs9k ldrl 
Original summary:237 238 3 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:0131 number humanized antibody molecules comprising antigen binding site derived non hu man immunoglobulin described including chi meric antibodies rodent modified rodent v regions associated cdrs fused human constant domains 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:alternative linking groups include limited to embodiments phosphate replaced p 0 s ate 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal binds isolated m antibody binds pcska comprising one 237 238 seq id no 3 wherein antibody blocks pcsk9 ldlr 
Original summary:237 238 3 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:also isolated monoclonal antibody wherein bound pure pcsk9 monoclonal antibody binds least one following residues s153 i154 sometimes p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 group seq id 10 wherein monoclonal fluorescent antibody blocks binding route pcsk9 ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 10 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:sonication less preferred purpose results level dna fragmentation 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:e regions pcsk9 contacted monoclonal antibodies 5ai 0 7d4 preparation described later herein determined protein tomography sidec b sweden 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:aspects invention comprises method lowering serum cholesterol level subject method comprising administering subject effective amount least one isolated antigen binding protein disclosed herein 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody in bound pcsk9 antibody binds least one following s153 i154 p155 r194 d238 a239 369 s372 d374 c375 t377 c378 v480 s381 seq id no 3 monoclonal antibody blockx pcsko ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:nviention claimed is monocalonl anibtody specifically binds k2 odmain knuitz domain 2 tfpi wherein sadi natiboyd specifically binds peiotpe ocmripsing reisudes e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:certain embodiments humanized antibody substantially affinity target antibody another species humanized antibody derived 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:claimed is 1 isolated monuc1ona1 antibody wherein bound tu pcsk9 said monoclonal antibody binds least one residue within sequence 8et forth residues 123 13z seq id n0 1 wherein said monoclonal antibody reduces binding 6etween pgsk9 egfa domain ldlr protein antagonizes pcsk9 inhibition cellolak lol uptake 
Original summary:123 132 1 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:and or cmss competing ant bodies encompassed useful meth ods disclosed hcrcin 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:independent isolated candidate monoclonal antibody wherein bound pcsk9 said monoclonal antibody binds length least one residue within sequence set forth determined residues 123 132 seq id chromosome 1 wherein said independent monoclonal antibody reduces binding pcsk9 egfa domain protein ldlr protein antagonizes pcsk9 inhibition cellular ldl uptake 
Original summary:123 132 10 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:n present invention used alone n combi conventional methods treatment p jsk9 antagonist antibody 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:10 illustrates dose dependence cho lesterol lowering effect anti pcsk9 antagonist antibody 5ai 0 mice 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:monoclonal antibody bound pcsk9 monoclonal binds least one following residues s153 i154 p155 r194 d238 a239 i369 s372 d 74 c375 t377 c37 fw79 v380 seq id no 3 wherein monoclonal antibody bpocks lcsk9 ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:exclusively isolated monoclonal antibody naturally binds pcsk9 wherein highly isolated monoclonal antibody binds epitope mouse pcsk9 comprising least one repeat residues b 277 278 strain seq id 8 7 also wherein monoclonal antibody blocks binding pcsk9 ldlr 
Original summary:277 278 8 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated mo antibody binds pcsk9 wherein d antibody binds epitope pcqsk9 c ileast one 237 238 seq id no 3 wherein m blocks binding pcsk 9 ldlr 
Original summary:237 238 3 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated antibody nound 9csk9 said monoclonal antibody binds least one residue within set fortj 544 582 seq id no 90 said monoclonal antibody reduces binding pcsk9 egfa domain ldlr pro antagonizes pcsk9 igh on cellular ldl uptake 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated animal monoclonal antibody wherein bound pcsk9 said monoclonal antibody binds least one residue within sequence set forth together residues 544 582 seq doc id ars 90 2000 wherein also said monoclonal human antibody reduces binding pcsk9 egfa domain substrate ldlr protein antagonizes pcsk9 inhibition cellular ldl uptake 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody binds pcsk9 identified wherein separated monoclonal antibody bonded matrix pcsk9 comprises least one 278 rna seq ids 277 ° c compound monoclonal antibody blockingthe binding pcsk9 ldlr 
Original summary:277 278 8 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated yeast monoclonal antibody wherein bound tightly pcsk9 said monoclonal antibody binds least one key residue within sequence set forth residues 544 582 seq id sigma 90 wherein said monoclonal antibody also reduces binding pcsk9 egfa ii domain ldlr protein antagonizes pcsk9 inhibition pathway mouse cellular ldl uptake 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:00ss vector means construct capable delivering and preferably expressing one gene s sequence s interest host cell 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:chothia definition similar kabat definition chothia definition takes account positions certain structural loop regions 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:group 3 4 animals infected virus day 4 average over 5 days 68 sem 18 animals infected 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:also understood reading definition that example antibody or moiety epitope specifi cally preferentially binds first target may may specifically preferentially bind second target 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody specifically binds hpcsk9 comprising a heavy chain complementarity determining region 1 hcdr1 comprising amino acid sequence least 95 identical seq id no 76 b heavy chain complementarity determining region 2 hcdr2 comprising amino acid sequence least 95 identical seq id no 78 c heavy chain complementarity determining region 3 hcdr3 comprising amino acid esqunece taht least 95 identical seq id no 80 d light chain complementarity determining region 1 lcdr1 comprising maino acid sequence least 95 identical seq id no 84 e light chain complementarity determining region 2 ldcr2 comprising amino acid sequence least 95 identical seq id no 86 f ligth chain complementarity determining region 3 lcdr3 comprising amino acid sequence least 95 identical seq id no 88 2 antibody antigen binding fragment natbiody claim 1 wherein antibody antigen ibndign fragenmt antibody binds epitope comprising amino acid residue 238 hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:monoclonal antibody isolated wherein monoclonal antibody specifically binds least one residue generated seq id no no 123 132 seq id no part 1 combined pcsk9 and combination monoclonal antibody reduces binding pcsk9 egfa structural domain ldlr binding proteins antagonize inhibition pcsk9 normal cell ldl 
Original summary:123 132 10 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:actual separated monoclonal antibody directly binds directly pcsk9 wherein isolated monoclonal antibody binds epitope activated pcsk9 comprises least one 4 residues 277 substance seq id no 8 wherein monoclonalmouse antibody blocked binds pcsk9 ldlr 
Original summary:277 278 8 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:second invention claimed monoclonal antibody design specifically binds k2 binding domain including kunitz domain 2 tfpi wherein said antibody specifically simply binds epitope comprising residues containing e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 ad seq id 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:polypeptides antibodies especially shorter polypeptides 50 amino acids conveniently made chemical synthesis 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:finally 40 μl well one step tmb neogen lexington ky added plate quenched 40 μl well 1n hydrochloric acid 30 minutes room temperature 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:detailed description invention monoclonal antibody k2 receptor domain kunitz domain 2 combination tfpi wherein cancer antibody specific binding comprises residues e10 e11 d12 p13 r17 y19 the epitope t21 truncated y23 f24 mutant n26 q28 q31 residues c32 e33 r34 k36 l50 residues seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated nql antibody wherein bound pcsk9 said monoclonal antibody binds one residue within sequence set residues 544 582 seq id no 90 said monoclonal reduces binding pcsk0 egfa doma n ldlr antagonizes pcsk9 inhibition ldl uprake 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal marker antibody wherein already bound pcsk9 bacterial monoclonal antibody binds least one following residues s153 i154 p155 r194 d238 a239 i369 s372 either d374 c375 t377 c378 f379 v380 s381 seq id site 3 3 wherein monoclonal antibody strongly blocks binding pcsk9 ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:' monoclonal body rs mui body obtained population substantially c tlm individual antibodies comprising population except lor possible naturally occurring mutations may present minor amounts 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:sequence similarity one index structural similarity however case theory’ defined above necessary assistor protein encoded expressed protein share single b cell epitope defined recognized single antibody agent without sequence homology 
Original summary:no data 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:mono clonal antibodies may isolated culture media body fluids conventional immunoglobulin purification procedures ammonium sulfate precipitation gel elec chromatography desired 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:substrate hrp detect unount ofmouse antibody present 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:18 2010 said pcsk9 negative host animal preparing antibody said antibody producing cell said antibody encoding nucleic acid 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antbidoy hwerien bound pcsk9 monoclonal antibody binds lesat one following residues s153 i145 p155 1r94 d238 a239 i369 s372 d374 c735 t377 c378 f379 v308 s381 seq id no 3 wherein omncoolnal antibody blocks bniidng pcsk9 ldrl 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody wherein bound specifically pcsk9 monoclonal antibody binds fairly least one following residues s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 etc s381 cancer seq id 3 wherein monoclonal antibody blocks binding pcsk9 ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated antibody wherein pxcsk9 monoclonal antibody binds least one following residues s153 i154 p155 r194 d238 a239 s372 d374 c375 t377 c378 s3 81 seq id no 3 wherein monoclonal antibody blocks fpcsk9 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibodies antigen binding fragments antibodies specifically binds hpcsk9 including a heavy chain complementary determination region 1 hcdr1 heavy chain complementary region 1 hcdr1 comprises amino acid substrate sequence amino acid substrate sequence amino acid substrate sequence seq id no 76 b heavy chain complementary determination region 2 hcdr2 comprising amino acid sequence least 95 seq id no 78 c short heavy chain complementary determination region indicia 3 hcdr3 comprising amino acid sequence least 95 seq id no 80 d light chain complementary determination harvest region 1 lcdr1 contains amino acids sequence least 95 seq id no 84 e light chain specific complementary determination region 2 lcdr2 comprising amino acid sequence least 95 seq id no 86 f light chain complementary determination region 3 lcdr3 comprising amino acid sequence least 95 seq id no 88 2 antibody antigen binding fragment claim 1 wherein antibody antigen binding fragment antibody binds epitope fragment comprising amino acid residue 238 hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody specifically binds hpcsk9 comprising a heavy chain complementarity determining region 1 hcdr1 comprising amino acid least 95 identical seq id no 76 b heavy chain complementarity determining region 2 hcdr2 comprising amino acid sequence least 95 identical seq id no 78 c heavy complementarity determining region 3 hcdr3 comprising amino acid sequence least 95 identical seq id no 80 d light chain complementarity determining region 1 lcdr1 comprising amino acid sequence least 95 identical seq id no 84 e light chain complementarity determining region 2 lcdr2 comprising amino acid sequence 95 identical seq id no 86 f light cha in complementarity determining region 3 lcdr3 g amino acid sequence least 95 identical seq id no 88 2 antibody antigen binding fragment antibody claim 1 wherein antibody antigen binding fragment binds epitope armino acid 238 hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:0138 dosing antagonist well within realm skilled artisan see e g et al 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:lil3 completely inhibits pcsk9 mediated regu lation ldlr cultured huh7 cells incubated 100 nm human murine pcsk9 antibody 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:may also serve target given glycoprotein molecules based n i spccilic recognition structures ai ti bod es also reported affect antibody dependent cellular cytotoxicity ai cc 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:effect pcsk9 specific antibodies pcsk9 antagonist vivo a pcsk9 antagonist antibodies lower serum cholesterol mice determine pcsk9 antagonist monoclonal anti bodies affect cholesterol levels vivo inhibiting function extracellular pcsk9 effect 7d4 tested mouse pcsk9 vitro serum cholesterol injected mice 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated wherein monoclonal an binds epitope comprising one residues 3 4 seq id no 5 wherein al antibody blocks binding 
Original summary:237 238 3 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding rfagmetn antibody specifically binds hpcsk9 comprising a heavy chain comlpementiaryt determining region 1 hcdr1 comprising amino acid sequence least 95 identical seq id no 76 b heavy chian complementarity determining region 2 hcdr2 comprising amino acid sequence least 95 identical seq id no 78 c heavy chain complementarity determining region 3 hcdr3 comprising amino acid sequence taht least 95 identical seq id no 80 d light cahin complementarity determining region 1 lcdr1 comprising amino acid sequence least 95 idneitcal seq id no 84 e light chain complementarity determining regoin 2 lcdr2 comprising amino acid sequence least 95 identical seq id no 86 f light chain complementarity determining region 3 lcdr3 comprising amino acid esquenec least 95 identical seq id no 88 2 antibody antigen binding fragment antibody claim 1 wherein antibody antigen binding fragment antiobyd binds epitope comprising amino acid residue 238 hpcks9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:modifier mono clonal indicates character antibody obtained substantially homogeneous population antibodies construed requiring production antibody particular method 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody specifically binds hpcsk9 comprising heavy chain complementarity determining region 1 hcdr1 comprising altogether amino acid sequence least 95 identical seq id 76 b heavy chain complementarity determining region region 2 hcdr2 comprising amino acid tag sequence least 95 identical seq id 78 c heavy chain complementarity determining region 3 hcdr3 comprising amino acid sequence least 95 identical seq id 80 light chain complementarity determining region 1 lcdr1 comprising amino acid sequence least 95 identical seq id 84 e light chain complementarity identifying determining region 2 lcdr2 comprising amino acid sequence least 95 identical seq id 86 f light chain complementarity determining region 3 lcdr3 comprising amino acid sequence least 95 identical seq id 88 2 antibody antigen binding fragment antibody claim 1 wherein antibody antigen binding fragment antibody group binds epitope comprising amino acid residue id 238 hpcsk9 seq id id 2 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:formulation capture elisa formulations immunisation table 2 assayed capture enzyme linked immunoadsorbent assay elisa ha a sichuan antigenicity 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:specific binding hpcsk9 antibody antigen binding identification fragment including a heavy chain complementary determination region 1 represented hcdr1 containing amino acid sequence amino acid sequence seq id no 76 b heavy chain complementary determinationregion 2 hcdr2 contains amino acid sequence almost amino acid sequence seq id no 78 c heavy chain complementary determination region 3 hcdr3 contains seq id no 80 amino acid sequence d unique light chain complementary determination region 1 lcdr1 comprising amino acid sequence least 95 seq id no 84 e light chain complementary determination region 2 lcdr2 it includes least 95 amino acid sequence seq id no 86 f light chain complementary determining region 3 lcdr3 comprising least amino acid sequence seq id no 88 antibody antibody binding fragment claim 1 wherein antibody antigen binding fragment therein antibody binds epitope amino acid residue 238 containing hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:is 1 isolated ody w n bound pcsk9 said monoclonal antibody binds least one residue sequence set forth 123 132 seq id no 1 wherein antibody reduces binding pcsk9 egfa domain ldlr protein pcsk9 inhibition cellular ldl 
Original summary:123 132 1 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:1991 sequences proteins immu interest fifth edition u s department health human services nih publication no 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:initially isolated monoclonal antibody wherein bound specific pcsk9 said blood monoclonal antibody binds least one residue within sequence set defined forth residues 544 582 seq accession id 90 wherein said monoclonal antibody reduces binding pcsk9 egfa domain ldlr protein antagonizes pcsk9 inhibition genes cellular ldl uptake 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:calcium phosphate may also used dna protein together resulting co formulation version invention described wo a 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:claimed is 1 isolated monoclonal wherein w en bound pcsk s id monoclonal binds least one residue within sequence set forth resid gs 123 132 seq id no 1 wherein said monoclonal antibody reduces binding be pcse9 egfa domain ldlr protein antagonizes cellular ldl uptake 
Original summary:123 132 1 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal atnibdoy binds pcsk9 wherein isolated monoclonal anbtiody binds epitope ocmpirsnig lesat one residesu 3 4 seq id no 5 wherein moocnlnoal antibody blocks ibndign pcsk9 ldlr 
Original summary:237 238 3 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:extent definitions terms provided references incorporated reference differ terms discussion provided herein present terms definitions control 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:wh t claimed is 1 isolated monoclonal antibody in bound pcsk9 said ody binds least one residue within sequence set forth residues 123 132 seq id no 1 antibody binding pcsk9 gfa domain ldlr protein antagonizes pcsk9 cellular ldl uptake 
Original summary:123 132 1 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isola fd monoclonal body binbs pcsk9 wherein isolated antibody b3nds comprising least one residues 3 4 seq id no 5 wherein antibody bindino pcsk9 ydlr 
Original summary:237 238 3 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:technology well known art fully detailed various publications including limited u s pat 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibodies useful present invention encompass monoclonal antibodies polyclonal antibodies antibody fragments e g fab fab' f ab' fv fc etc 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody wherein bound pcsk9 monoclonal antibody binds least one following residues s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 f379 v380 seq io no 3 wherein monoclonal antibody blocks 6indin9 pcsk9 ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 
Predicted summary: s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:example pcs k9 specific antagonists may used combination conjunction drugs therapeutic and or tic including limited cholesterol lowering drugs example cholesterol absorption inhibitors e g zetia cholesterol synthesis inhibitors e g zocor 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:certain embodiments humanized antibodies modified eliminate glycosylation sites order increase affinity antibody cognate antigen 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated y that pcsk9 wherein isol antibody pcsk9 comprising least one residues 237 238 seq id no 3 wherein monoclonal antibody bl4ocks binding pcsk9 lqdlr 
Original summary:237 238 3 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:one skilled art appreciate appropriate dosage levels treatment according certain embodiments thus vary depending part upon molecule delivered indication antigen binding protein pcsk9 without least one additional therapeutic agent used route administration size body weight body surface organ size and or condition the age general health patient 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:atniobdy antigen bidnnig fragment antibody specifically binds hpcsk9 comprising a heavy chain compelemntarity determining region 1 hcdr1 comprising amino acid sequence least 95 identical seq id no 76 b heavy chain complementarity determining region 2 hcdr2 comprising maino caid sequence least 95 identical seq id no 78 c heavy hcain complementarity edtremiinng region 3 hcdr3 comprising amino acid sequence least 95 identical seq id no 80 d light chain oclmpemnetarity determining region 1 lcdr1 comprising amino acid sequence least 95 identical seq id no 84 e light chain complementarity determining region 2 lcdr2 comprising amino acid sequence least 95 identcila seq id no 86 f light chain complementarity determining region 3 lcdr3 comprising amino acid sequence least 95 identical seq id no 88 2 antibody antigen binding fragment antibody claim 1 wherein antibody antigen binding fragment antibody binds epitope comprising amino acid residue 238 hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:is al antibody k2 kunitz domain 2 tfpi wherein said binds ope comprising s e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:3 773 919 copolymers l glutamic acid 7 ethyl l glutamate non degradable ethylene vinyl acetate degradable lactic acid glycolic acid copolymers injectable microspheres composed lactic acid glycolic acid copoly mer acetate sucrose acetate isobutyrate poly d — 3 acid 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:embodiments remain stable 3 months 6 months 12 months 2 years longer periods temperatures 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:types competitive binding assays used determine one antigen binding protein competes another example solid phase direct indirect radioimmunoassay ria solid phase direct indirect enzyme immunoassay eia sandwich competition assay see e g et al 1983 methods enzymology 9 242 253 solid phase direct biotin avidin eia see e g et al 1986 j immunol 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:table 6 sample sample sample mg ml buffer um hpcsk9 1 26 pbs 16 6 mpcsk9 1 44 pbs 18 9 cpcsk9 v5 0 22 pbs 2 9 16f12 anti pcsk9 4 6 20 mm naoac ph 31 9 5 2 50 mm nacl 21b12 anti pcsk9 3 84 10 mm naoac ph 27 0 5 2 9 sucrose 31h4 anti pcsk9 3 3 10 mm naoac ph 22 9 5 2 9 sucrose affinity measurements surface plasmon resonance device biacore inc piscataway n j affinity analysis 21b12 antibodies pcsk9 described example performed according manufacturer instructions 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:range provided as example about 50 200 expressly includes distinct embodiments number within said range 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:0147 non viral delivery vehicles methods also employed including limited to con dna linked adenovirus alone see e g 1992 hum 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:heavy chain residues within 5 angstroms include following s31 y32 s54 r98 y100 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:us 2009 0246192 a1 15 oct 1 2009 nucleic acids present invention obtained using standard molecular biology techniques 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated antibody comprising heavy clmin variable region vi i mid light chain variable region vl h vi region comprises actd sequence slq id no 54 vl region comprises amino acid sequence sfq id 53 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:pcsk9 specific antagonists possessing one conservative amino acid substitutions retain ability selectively bind human pcsk9 antagonize pcsk9 functioning level better d05 antibody molecules described herein referred herein func tional equivalents disclosed antagonists form specific embodiments present invention 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:claimed is monoclonal antibody t hat spec binds k2 domain domain 2 tfpi wherein sa id ibody spec ly beinds comprising e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:claimed is 1 iso onal antibody wherein wheb bound pcsk9 said monoclonal antibody binws leazt one residue within sequence set rorth 123 132 seq id no 1 wherein said monoclonal antibody reduces pcsk9 domain ldlr protein pcsk9 inhibition cellular ldl uptake 
Original summary:123 132 1 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:claimed type 1 isolated monoclonal marker antibody either wherein bound pcsk9 said candidate monoclonal antibody binds least one residue within sequence set forth residues 123 132 seq id 1 wherein said monoclonal antibody reduces binding bound pcsk9 egfa domain ldlr 5 protein antagonizes pcsk9 inhibition cellular ldl uptake 
Original summary:123 132 1 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen fragment specifically binds hpcsk9 comprising a heavy chain complementarity determining region 1 hcdr1 comprising amino acid sequence least 95 identical seq id no 76 b heavy chain co pl determining region 2 hcdr2 comprising amino acid sequence least 95 identical seq id no 78 c heavy chain complementarity determining region 3 hcdr3 comprising amino acid sequence least 95 identical seq id no 80 d light chain determining 1 lcdr1 comprising amino acid sequence least 95 identical seq id no 84 e light chain c determining 2 comprising amino sequence least 95 identical seq id no 86 f light chain complementarity determining region 3 lcdr3 comprising amino acid sequence least 95 identical seq id no 88 2 antibody antigen binding fragment antibody claim 1 wherein antibody antigen binding fragment ant binds epitope comprising amino acid residue 238 hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:wntibldy binding fragment antibody specifically binds hpcski comprising a heavy chain complementarity determining region 1 hcdr1 comprising amino acid sequence least 95 identical seq id no 76 b heavy chain complementarity determining rerion 2 hcdr2 amino acid sequence thaf l ast 95 identical seq id no 78 c heavy chain complementarity determining region 3 hcdr3 comprising amino acid sequence least 95 identical seq id no 80 d light chain complementarity determining region 1 lcdr1 comprising amino acid sequence least 95 identical seq id no 84 e light chain complementarity determining region 2 comprising amino acid sequence least 95 identical seq id no 86 f light chain complementarity determining rdgion 3 lcdr3 comprising amino acid sequence least 95 identical seq id no 88 2 antibody antigen binding fragment antibody claim 1 wherein antibody antigen binding fragment antibody binds epitope comprising amino acid residue 238 hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:three antibodies end heavy chain dark differs well amino acids structure appear coordinates 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:monoclonal antibody monoclonal immune antibody residues 123 132 residues 123 132 residues 123 132 cat seq id no 1 combined pcsk9 base binding monoclonal antibody reduces inhibition inhibitory cells pcsk9 pcsk9 promoter domain containing domain ldlr proteins ldl 
Original summary:123 132 10 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:certain embodiments parenteral compositions generally placed container sterile access port example intravenous solution bag vial stopper pierceable hypodermic injection needle 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody y vinds hpcsk9 comprising a heavy chain complementarity determining region 1 hcdr1 comprising amino acid sequence least 95 seq id no 76 b heavy chain determining region 2 hcdr2 comprising amino acid sequence keast 95 identical seq id no 78 c chain complementarity determining region 3 hcdr3 comprising amino acid sequence least 95 identical seq id no 80 d light chain complementarity determining region 1 lcdr1 comprising amino acid sequence least 95 identical seq id no 84 e light chain complementarity determining region 2 lcdr2 comprising a ino acid thqt least 95 identical seq id no 86 f light chain complementarity determining region 3 lcdr3 comprising amino acid sequence least 95 identical seq id no 88 2 antibody antigen binding fragment antibody claim 1 wherein antibody antigen fragment antibody binds epitope comprising amino acid residue 238 hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:embodiments antibody positioned 5 angstroms less least two following residues pcsk9 s153 s188 i189 q190 s191 d192 r194 e197 g198 r199 v200 d224 r237 d238 k243 s373 d374 s376 t377 f379 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated selective monoclonal antibody identified binds exclusively pcsk9 wherein already isolated monoclonal antibody binds epitope expressed pcsk9 comprising least one residues 277 278 seq id component 8 wherein established monoclonal antibody blocks binding substrate pcsk9 ldlr 
Original summary:277 278 8 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:certain embodiments antigen binding protein comprises light chain comprising variable region comprising amino acid sequence least 95 identical amino acid sequence selected least one sequences seq id no 5 7 9 10 12 13 15 16 17 18 19 20 21 22 23 24 26 28 30 31 32 33 35 36 37 38 39 40 42 44 46 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:ui mediated mutagenesis wluch mutated nucle nre incorporated tlm p tluit pcr product desired mutations site directed mutagenesis 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:another antibodies peptides cml made recombinantly using procedures tlmt well known art 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:subsequent 5 ug doses injection method intraperitoneal injections abdomen sub injections base tail 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:claimed is 1 isolated lonal antibody wherein bound ptcsk9 sa9id monoclonal binds least one e within sequence set forth 123 132 seq id no 1 wherein monoclonal an binding pcsk9 egfa domain ldlr protein antagonizes opcsk9 inhibition cellular ldl uptake 
Original summary:123 132 1 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:formulation 2 1 consisted ha dna protein co delivered liposomal formulation produces greater response formulations sera sample bleed tested day 28 day 56 day 28 following second dose 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:example 22 use pcsk9 antibodies diagnostic agent enzyme linked immunosorbent assay elisa detection pcsk9 antigen sample used diagnose patients exhibiting high levels pcsk9 production 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:embodiments abp agent administered simultaneously abp administered agent administered 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:amino acids met distance criteria calculated program w l molecular system 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated antibody bindrs pcsk9 wherein bi nds e comprising one residues 3 4 seq id no 5 wherein antibody blocks binding ldlr 
Original summary:237 238 3 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:thereby isolated monoclonal antibody wherein monoclonal antibody illustrates least sequence residues 123 132 residues 123 132 transduc id no 1 pcsk9 bonded a residue sequence bonded monoclonal antibody reduces binding pcsk9 ldlr protein antagonizing inhibitory effect pcsk9 cell ldl oxygen absorption 
Original summary:123 132 10 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody wherein also bound specifically pcsk9 said different monoclonal antibody binds least one residue within independent sequence set forth residues 544 582 seq id 90 wherein said monoclonal antibody reduces binding pcsk9 wherein egfa domain containing another ldlr protein antagonizes pcsk9 inhibition acute cellular ldl uptake 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:1 h 37° c plates washed four times pbst overlaid 50 μl well substrate solution 3 3′ 5 5′tetramethyl benzidine tmb pierce 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody specifically binds hpcsk9 comprising a heavy chain complementarity determining region 1 comprising amino acid sequence least 95 identical seq id no 76 b heavy chain complementarity determining region 2 hcdr2 comprising amino acid sequence leasg 95 seq id no 78 c heavy chain complementarity determining region 3 hcdr3 comprising amino sequence least 95 identical seq id no 80 d light chain complementarity determining region 1 lcd 1 comprising amino acid sequence leqst 95 identical seq id no 84 e light chain complementarity ng region 2 lcdr2 comprising amino acid sequence least 95 identical seq id no 86 f light chain complementarity determining 3 lcdr3 comprising amino acid sequence least 95 identical seq id no 88 2 antibody antigen binding fragment antibody claim 1 wherein antibody antigen binding fragment antibody binds epitope comprising amigo acic residue 238 hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:aspects invention comprises method increasing ldlr protein levels subject administering subject effective amount least one isolated antigen binding protein described herein simultaneously sequentially agent elevates availability ldlr protein 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:5 comprising mg ml 200 mg ml antibody mil limolar 100 millimolar histidine buffer 0 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding antibody specifically binds hpcsk9 comprising a heavy chain complementarity determining region 1 hcdr1 comprising amino acid sequence least 95 identical seq id no 76 b heavy chain region 2 hcdr2 comprising amino acid sequence least 95 identical seq id no 78 c heavy chain complementarity determining region 3 hcdr3 comprising amino acid sequence chat least 95 identical seq id no 80 d light chain complementarity determining 1 lcdr1 comprising amino acid sequence least 95 identical seq id no 84 e light chain complementarity determining region 2 lcdr2 co ing anino acid sequence least 95 identical seq id no 86 f light chain complementarity determining 3 lcdr3 amino acid sequence least 95 seq id no 88 2 antibody antigen binding fragment antibody claim 1 wherein antibody antigen binding fragment antibody binds epitope comprising amino acid residue 238 hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:23a s crystal structure pc'sk9 surface representation bound 3 antibody black 23b depicts ihc i'csk9 light surface representation bound like ol'lm i di r black cartoon representation kwon et al pnas 105 1820 2008 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:specifically regards anti us 2009 0246192 a1 17 oct 1 2009 body molecules antibody light chain gene anti body heavy chain gene inserted separate vectors or typically genes may inserted expression vector 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:typically assay involves use purified antigen bound solid surface cells bearing either test antigen binding protein labeled reference antigen binding protein 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody binsd pcsk9 wherein isoladte monoclonal naitbody binsd eipotpe pcsk9 comprising elast one residues 237 238 seq id no 3 hwreein monocolnal antibody blocks ibndnig pcks9 ldlr 
Original summary:237 238 3 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:specific theory specific theory states enhanced performance appropriately co formulated material wherein dna cognate protein associated single vesicle vesicles population dna protein involves targeting by antigen protein form exposed surface particle vesicle antigen specific b cells thereby selectively delivering dna cognate protein targeted manner antigen specific b cell 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:invention claimed example new monoclonal antibody specifically indirectly binds k2 domain also kunitz domain 2 tfpi often wherein said antibody specifically binds epitope comprising residues e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 xl l50 seq id 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:light separate mid suitable host 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:certain embodiments polypeptides comprising one abp components abp made bacterial cells produced insoluble inclusion bodies bacteria 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:heavy chain residues 5 8 å pcsk9 protein include following w47 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:another embodiment vector introduced cells lipofection transfection facilitating agents peptides polymers etc 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:mutations express tlm p sk9 antibodies tlm present invention dna fragments encoding v» v regions first 1 obtained using methods described various modifications c g 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody specifically binds hpcsk9 comprising special heavy chain complementarity determining region 1 hcdr1 comprising amino final acid sequence least 95 identical seq id 76 b heavy chain complementarity determining region 2 also hcdr2 comprising amino terminal acid sequence least 95 identical seq id 78 c heavy chain complementarity determining region 3 hcdr3 comprising amino acid sequence least 95 identical seq id 80 light chain exclusive complementarity determining region 1 lcdr1 comprising amino acid sequence usually least 95 identical seq id 84 e light chain dependent complementarity determining region 2 lcdr2 comprising amino acid sequence either least 95 identical seq id 86 f light chain complementarity determining region 3 lcdr3 comprising amino acid sequence least 95 identical seq id 88 2 antibody antigen binding fragment antibody claim 1 wherein antibody antigen binding fragment antibody binds amino epitope comprising amino acid residue 238 hpcsk9 seq id 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:such probable larger variations light chain cdrs possible without unduly interfering binding antigen binding protein pcsk9 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody specifically binds hpcsk9 comprising a heavy chain complementarity determining region 1 hcdr1 comprising amino acid sequence least 95 identical seq id no 76 b heavy chain complementarity determining region 2 hcdr2 comprising amino acid sequence least 95 identical seq id no 78 c heavy chain complementarity determining region 3 hcdr3 amino acix e least 95 seq id no 80 d light complementarity determining region 1 lcdr1 comprising amino acid sequ least 95 identical seq id no 84 e light chain complementarity determining region 2 lcdr2 comprising amino acid sequence least 95 identical seq id no 86 f chain complementarity determining region 3 lcdr3 comprising amino acid sequence least 95 identical seq id no 88 2 antibody ap igen binding fragment antibody claim 1 wherein antibody antigen binding antibody binds epitope comprising amino acid residue 238 hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:cell considered transforming dna replicated division cell 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:methods used calculate identity aligned nucleic acids polypeptides include described molecular biology a m ed 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:claimed 1 independently isolated monoclonal antibody wherein bound designated pcsk9 said monoclonal antibody likely binds least one residue within sequence set forth residues 123 132 seq id 1 wherein said monoclonal based antibody reduces binding pcsk9 proteins egfa domain structure ldlr protein antagonizes pcsk9 inhibition process cellular induced ldl uptake 
Original summary:123 132 1 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:iolsated monoclonal antibody binsd pcsk9 hwerien isloatde moncolnola tanibody binds epitope comprising least one residues 3 4 seq id no 5 wherein monoclonal anibtody bolcks ibnidng cpsk9 ldlr 
Original summary:237 238 3 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:cliamde is 1 islotaed monoclonal antibody wherein bound psck9 said monoclonal antibody binds least one residue wihtin sequence set forth residues 123 132 seq id no 1 whreein said monoclonal antibody redusce binding pcs9k egfa domain ldrl protein antagonizes pcsk9 inhibtinio cellular ldl uptake 
Original summary:123 132 1 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:cvd underlying atherosclerosis cause among groups despite availability therapies directed multiple risk factors 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated monoclonal antibody wherein bonud pcs9k said moconlonal antibody ibnds least one residue wtihin sequneec set forth residues 544 582 seq id no 90 wherein said omonclnoal natiobdy reduesc binding pcsk9 egfa domain ldlr protein antagonizes pcsk9 hinibitino cellular ldl uptake 
Original summary:544 582 90 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isolated omonclonla antibody whreein boudn pcsk9 monoclonal antibody bidns least one following residues s153 i154 p515 r194 d238 a239 i369 s372 d347 c375 t377 c378 f739 v380 s318 seq id no 3 wherein monoclonal antibody blocks binding pcsk9 ldlr 
Original summary:s153 i154 p155 r194 d238 a239 i369 s372 d374 c375 t377 c378 f379 v380 s381 3 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:actual isolated monoclonal human antibody directly binds pcsk9 wherein isolated monoclonal antibody binds epitope activated pcsk9 comprising least one 4 residues 277 regulation 278 substance seq id 8 wherein monoclonal mouse antibody blocks binding bound pcsk9 ldlr 
Original summary:277 278 8 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:claimed is binds k2 xomain kunitz domain 2 yfpi wherein said ant specifically binds vompr e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:following rehydration controlled conditions generated dehydrated rehydrated vesicles drv liposomes washed centrifugation remove non incorporated dna 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:claim new invention monoclonal antibody complex specifically binds tfpi k2 binding domain kunitz domain 2 wherein antibody specific binding comprises residues e10 e11 d12 p13 r17 the epitope y19 t21 particularly y23 f24 n26 including q28 q1 c32 e33 r34 k36 320 l50 seq code id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:embodiments include isolated pcsk9 specific antagonist and specific embodiments antibody molecules comprise light chain variable region sequence found seq id nos 57 60 optionally comprising heavy chain variable region sequence disclosed herein e g seq id no 11 specific embodiments inhibit human and or murine pcsk9 dependent inhibition cellular ldl uptake least 10'zo 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment antibody specifically binds hpcsk9 comprising a heavy chain complementarity determining region 1 hcdr1 comprising amino acid sequence least 95 identical seq id no 76 b heavy cmain complementarity determining region 2 hcdr2 comprising amino acid sequence least 95 seq id no 78 c chain complementarity determining 3 hcdr3 comprising amino acid sequence least 95 identical seq id no 80 d light chain complementarity determining region 1 lcdr1 comprising amino acid least 95 identical seq id no 84 e light chain complementarity determining region 2 lcd 2 comprising amino acid sequence least 95 identical seq id no 86 f light chain complementarity region 3 lcdr3 comprising amino acid least 95 identical seq id no 88 2 antibody antigen binding fragment antivowy claim 1 wherein antibidy antigen binding fragment antibody binds epitope comprising amino acid residue 238 hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:claimed 1 isolated monoclonal antibody wherein bound directly pcsk9 said identified monoclonal antibody domain binds adjacent least one residue within sequence set made forth residues 123 132 seq id section 1 2 wherein said monoclonal antibody reduces binding pcsk9 egfa domain ldlr protein antagonizes pcsk9 inhibition cellular ldl uptake 
Original summary:123 132 1 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:one fiision polypeptide provided lmist 10 contiguous anuno acids venable light reyon shown ui seq id nos 53 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:alternatively size control may involve additional step following step d suspension subjected passage 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:humanized antibody comprising light heavy chain variable regions one cdrs antibody variants shown table i one cdrs derived antibody variants shown table 2 made using methods known art 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:otherwise isolated monoclonal antibody binds pcsk9 wherein isolated suspected monoclonal antibody binds epitope pcsk9 comprising least one residues 277 278 b seq id 8 wherein monoclonal antibody strictly blocks binding routes pcsk9 ldlr 
Original summary:277 278 8 
Predicted summary: 237 238 3 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:isoltead monoclonal atniboyd binds cpsk9 wherein isolated monoclonla antiobyd binsd peitoep pcs9k comprising least one residues 237 238 seq id no 3 ewhrein monoclonal antibody blocks bdining pcsk9 ldlr 
Original summary:237 238 3 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:invention claimed is monoclonal antibody kinds k2 domain dombin 2 wherein uaid antibody specifically bi ds e rising residues e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 seq id no 2 
Original summary:e10 e11 d12 p13 r17 y19 t21 y23 f24 n26 q28 q31 c32 e33 r34 k36 l50 2 
Predicted summary: 123 132 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:tope mapping binding ant bodies using crystal structure li i 3 p 'sk9 complex biacore s crystal structure ol 1 11 3 p 'sk9 complex 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:alternatively independent isolated monoclonal antibody wherein bound pcsk9 whereby said monoclonal antibody binds least one major residue unique within sequence set forth residues 544 582 seq id entry 90 wherein said monoclonal antibody reduces rna binding target pcsk9 egfa domain ldlr protein antagonizes pcsk9 inhibition cellular ldl uptake 
Original summary:544 582 90 
Predicted summary: start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:antibody antigen binding fragment specifically binding hpcsk9 including a heavy chain complementary determination region 1 hcdr1 comprising amino acid sequence least 95 seq id no 76 b chain complementary determination region 2 hcdr2 contains amino acid sequence least 95 seq id no 78 c heavy chain complementary determination region 3 standard hcdr3 containing amino acid sequence least 95 seq id no 80 d light chain complementary determination region 1 lcdr1 comprising amino acid sequence least 95 seq id no 84 e novel chain complementary analysis determined region2 lcdr2 further overall amino acid sequence least 95 8 f seq id no 86 8 f light chain complementary determination region 3 lcdr3 contains least 95 seq id no 88 amino acid sequence 2 the antibody antigen binding fragment residue claim 1 wherein antibody antigen binding fragment antibody binds epitope comprising amino acid residue 238 hpcsk9 seq id no 755 
Original summary:238 755 
Predicted summary: 238 755 start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
Claim:278 457 listing human framework regions said disclosure incor porated herein reference entirety 
Original summary:no data 
Predicted summary: no data start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start start
